Clinical trial NCT01780454
Conditions: End Stage Renal Disease
Keywords: End Stage Renal Disease Renal Transplant Bone Marrow Transplant Tolerance Chimerism ESRD
Sponsor: Massachusetts General Hospital
Start date: 2013-03-01; Completion date: 2020-06-01
Enrollment: 2 participants; Allocation: NA; Intervention model: SINGLE_GROUP

Brief summary:
This study will examine the safety and effectiveness of a combination kidney and bone marrow transplant from a haplo-identical related donor. An investigational medication and other treatments will be given prior to and after the transplant to help protect the transplanted kidney from being attacked by the body's immune system

Detailed description:

Arms: arm 1: Conditioning regimen consisting of Rituximab, MEDI-507, Total Body Irradiation, Thymic Irradiation followed by simultaneous bone marrow and kidney transplantation
Interventions: intervention 1: MEDI-507 intervention 2: Rituximab intervention 3: Total Body Irradiation intervention 4: Thymic Irradiation
Intervention descriptions: intervention 1: T-Cell Depleting Agent intervention 2: B-Cell Depleting Agent intervention 3: Bone Marrow Depletion intervention 4: None

Protocol documents:
Prot_SAP_000.pdf: 
 
 
 
 
 
 
 
Renal Allograft Tolerance Through Mixed Chimerism 
 
 
Version 3.0 (January 27, 2014) 
 
 
 
 
 
Co-Principal Investigator: 
 
A.Benedict Cosimi, MD 
David H. Sachs, MD 
Tatsuo Kawai, MD, PhD 
 
Coinvestigators: 
 
James Markmann, MD, PhD 
Nina Tolkoff-Rubin, MD 
Thomas Spitzer, MD 
Robert B Colvin, MD 
Rex-Neal Smith, MD 
Susan Saidman, PhD 
Joren Madsen, MD, D.Phil. 
Jay Fishman, MD 
Nahel Elias, MD 
Winfred Williams, MD 
Yi-Bin Chen, MD 
Bimal Dey, MD 
Steve McAfee, MD 
Karen Winkfield, M.D. Ph.D. 
Fred Preffer, PhD 
Gilles Benichou, PhD 
 
 
 
Study Coordinator 
Kerry Crisalli, RN 
 
 
 
 
 1 


 
Synopsis 
 
Title 
 
 
Renal Allograft Tolerance Through Mixed Chimerism 
 
Short Title 
 
Renal Allograft Tolerance 
 
IND Sponsor 
 
David H Sachs 
 
IND # 
 
 
BB-IND 10181 
 
Trial Phase 
 
Phase I/II 
 
Conducted by  
MGH, Transplant Surgery  
 
Principal Investigators A. Benedict Cosimi, MD     
David H Sachs, MD  
Tatsuo Kawai, MD, PhD 
 
Accrual Objective 
2 participants with end-stage renal disease (ESRD) and no evidence of prior 
sensitization, and their donors 
 
Study Design 
 
Pilot study 
 
Pace of Enrollment  
Enrollment will be limited to one patient every three months  
and Study Duration 
  
 
 
Participants will be followed for a total of 5 years after combined bone marrow 
and kidney transplantation.  Assessments will be performed for participant and 
graft survival, and long term adverse events. 
 
Endpoint 
The primary endpoint is Induction of transient mixed chimerism and renal 
allograft tolerance without “engraftment syndrome” or “acute kidney injury”.  
 
 
 
Recipient Inclusion Criteria 
 
 
1.   Male or female 18–60 years of age. 
 
2.   Candidate for a living-donor renal allograft with a one haplotype identical donor identified. 
 
3.   First or second transplant with either a living donor or cadaveric transplant as the first transplant. 
 
4.   Use of FDA-approved methods of contraception (those with less than a 3% failure rate) by all 
recipients from the time that study treatment begins until 104 weeks (24 months) after renal 
transplantation. (For further information on FDA- approved methods of contraception, see  
http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118465.htm 
 
 2 


 
5. Ability to understand and provide informed consent. 
 
6. Serologic evidence of prior exposure to EBV.  
 
 
Recipient Exclusion Criteria 
 
1. 
ABO blood group-incompatible renal allograft. 
 
2. 
Evidence of anti-HLA antibody within 60 days prior to transplant as assessed by routine 
methodology (AHG and/or ELISA)  
 
3. 
Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia. 
 
4. 
Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (confirmed by hepatitis C     
virus RNA); or positivity for hepatitis B surface antigen. 
 
5. 
Cardiac ejection fraction < 40% or clinical evidence of insufficiency.  
 
6. 
Forced expiratory volume FEV1 < 50% of predicted.  
 
7. 
Lactation or pregnancy. 
 
8. 
History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix.  
 
9. 
Underlying renal disease etiology with a high risk of disease recurrence in the transplanted 
kidney (such as focal segmental glomerulosclerosis, type I or II membranoprolifertive 
glomerulonephritis).  
 
10. 
Prior dose-limiting radiation therapy. 
 
11. 
Known genetic disease or family history that may result in greater sensitivity to the effects of 
irradiation, or a physical deformity that would preclude adequate shielding or appropriate 
dosing during the irradiation component of the conditioning regimen. 
 
12. 
Enrollment in other investigational drug studies within 30 days prior to enrollment. 
 
13. 
 Abnormal (>2 times lab normal) values for (a) liver function chemistries (ALT, AST, AP), (b) 
bilirubin, (c) coagulation studies (PT, PTT). 
 
14. 
 Allergy or sensitivity to any component of MEDI-507, tacrolimus, or rituximab. 
 
15. 
Maintenance immunosuppression within 3 months prior to conditioning other than 
physiological doses of steroids, defined as ≤ 50 mg of hydrocortisone or dose equivalent. 
 
16. 
The presence of any medical condition that the investigator deems incompatible with 
participation in the trial. 
 
 3 


 
Donor Inclusion Criteria 
 
 
1.  Male or female 18–65 years of age. 
 
 2.   For females of childbearing potential: a serum pregnancy test showing negative results. 
 
3. Excellent health per conventional predonor history (medical and psychosocial evaluation). 
 
4.  Acceptable laboratory parameters (hematology in normal or near-normal range; liver 
function <2 times the upper limit of normal, and normal creatinine). 
 
5.   Negative for viral infection with HbsAg, HIV, HCV, or HTLV-1. 
 
6.   Cardiac/pulmonary function within normal limits (CXR, ECG). 
 
7. Ability to understand and provide informed consent. 
 
8. Meets standard institutional criteria for both bone marrow and kidney donation 
 
Treatment Description  
 
Recipients will receive a conditioning regimen that starts with Rituximab on day –7 (and 
days –2, 5, 12), Whole Body Irradiation 150 cGy x2  on study days –5 and –4, followed by 
MEDI-507, a T-cell-depleting agent, will be administered on days –2, –1, 0, and 1. Thymic 
irradiation (700 cGy) will be given on study day –1, and combined renal and bone 
marrow transplant will be done on study day 0. Prednisone will be started at 2 mg/kg on 
day 4 and tapered off by day 20. Tacrolimus will be administered on study days –1 
through 60, and then tapered if weaning criteria are met. Leukapheresis will be 
performed prior to initiating the conditioning regimen and these cells will be frozen 
 
All patients who require a blood transfusion will receive only leukocyte-depleted and 
irradiated blood products for a period of at least 52 weeks following transplantation. 
 
The proportion of patients not suffering “engraftment syndrome” and successfully 
weaned off immunosuppression will be assessed.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 4 


 
Glossary of Abbreviations 
 
AHR 
 
acute humoral rejection  
ALC 
 
absolute lymphocyte count  
ANC 
 
absolute neutrophil count  
APC 
 
Antigen-presenting cell(s)  
ATG 
 
antithymocyte globulin  
ATGAM  
lymphocyte immune globulin 
ATN 
 
acute tubular necrosis 
BMT 
 
bone marrow transplantation 
CBC 
 
complete blood count 
CFR 
 
Code of Federal Regulations 
CKBMT  
Combined kidney and bone marrow transplant 
CIS 
 
carcinoma in situ 
CML 
 
cell-mediated lysis, cell-mediated lympholysis 
CMV 
 
cytomegalovirus 
CRF 
 
case report form 
CTCAE  
Common Terminology Criteria for Adverse Events 
CTL 
 
cytotoxic T lymphocyte 
CVVH  
continuous veno venous hemodialysis 
ELISA 
 
enzyme-linked immunosorbant assay  
ELISPOT  
enzyme-linked immunospot (assay)  
ESRD 
 
end-stage renal disease 
GVHD  
graft-versus-host disease  
GCP 
 
Good Clinical Practice  
HLA 
 
human leukocyte antigen  
HTL 
 
helper T lymphocyte 
ICH 
 
International Conference on Harmonisation 
IND 
 
investigational new drug  
IRB 
 
institutional review board  
ITN 
 
Immune Tolerance Network  
LDA 
 
limiting dilution analysis 
MGH 
 
Massachusetts General Hospital 
MHC 
 
major histocompatibility complex 
MLR 
 
mixed lymphocyte response, mixed lymphocyte reaction 
NCI-CTCAE 
National Cancer Institute-Common Terminology Criteria for Adverse Events 
NK 
 
natural killer (cell) 
PBMC  
peripheral blood mononuclear cell(s) 
PCP 
 
Pneumosystis carinii pneumonia 
PRA 
 
panel-reactive antibody; panel reactivity assay  
PTLD 
 
post-transplant lymphoproliferative disease  
RTEC 
 
renal tubular epithelial cell(s) 
RT-PCR  
real-time polymerase chain reaction 
SAE 
 
serious adverse event 
SAEC 
 
safety adverse event coordinator 
SAP 
 
statistical analysis plan 
SI 
 
Stimulation Index  
TBI 
 
total body irradiation  
 5 


 
TI 
 
thymic irradiation 
TREC 
 
T-cell receptor excision circle(s) 
Treg 
 
regulatory T cell 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 6 


 
 
Table of Contents  
 
1. BACKGROUND.........................................................................................................................................12 
 
1.1 SUMMARY.............................................................................................................................................12 
 
1.2 PRECLINICAL AND CLINICAL STUDIES....................................................................................................15 
 
1.2.1 Preclinical Studies ............................................................................................................................ 16 
 
1.2.2 Clinical Studies: Prior Studies ........................................................................................................... 16 
 
1.3 RISKS TO PARTICIPANTS.......................................................................................................................21 
 
1.3.1 MEDI-507 ......................................................................................................................................... 21 
 
1.3.2  Rituximab (Rituxan®) ...................................................................................................................... 22 
 
1.3.3  Low Dose Total Body Irradiation .................................................................................................... 23 
 
1.3.4    Thymic Irradiation ......................................................................................................................... 23 
 
1.3.5 
Tacrolimus.................................................................................................................................... 23 
 
1.3.6 
Prednisone................................................................................................................................... 23 
 
1.3.7 
GVHD ........................................................................................................................................... 24 
 
1.3.8 
Renal Graft Failure ....................................................................................................................... 24 
 
1.3.9 
Infection ....................................................................................................................................... 24 
 
1.3.10 Bone Marrow Transplant-related Mortality................................................................................. 25 
 
1.3.11 Renal Biopsies .............................................................................................................................. 25 
 
1.3.12 Leukapheresis .............................................................................................................................. 25 
 
1.3.13 Engraftment Syndrome ............................................................................................................... 25 
 
1.3.14   ATG (Thymoglobulin and ATGAM) ………………………………..........................…………………………………..26 
 
1.4 
RISKS TO DONORS..........................................................................................................................26 
 
1.4.1 
Bone Marrow Donation ............................................................................................................... 26 
 
1.4.2 
Kidney Donation .......................................................................................................................... 27 
 7 


 
 
1.4.3 
Combined BMT and Kidney Donation............................................................................................27 
 
1.5 
RATIONALE FOR SELECTION OF CONDITIONING REGIMEN...........................................................27 
 
2 
STUDY DESIGN ..............................................................................................................................28 
 
2.1 
DESCRIPTION .................................................................................................................................28 
 
2.2 
CONSENT FOR PARTICIPATION......................................................................................................28 
 
2.3 
STUDY ENDPOINTS ........................................................................................................................28 
 
2.3.1 
Primary Endpoint.......................................................................................................................... 28 
 
2.4 
STOPPING RULES...........................................................................................................................28 
 
2.4.1 
Ongoing Review............................................................................................................................ 28 
 
2.4.2 
Review of Specific Adverse Events .............................................................................................. 29 
 
2.4.3  Data Monitoring Committee …………………….....................…………………………………………………………..29 
 
2.5 
ENROLLMENT, TIMING OF TRANSPLANT, AND LENGTH OF FOLLOW-UP .....................................29 
 
3 
ELIGIBILITY ....................................................................................................................................29 
 
3.1 
RECIPIENT INCLUSION CRITERIA....................................................................................................30 
 
3.2 
RECIPIENT EXCLUSION CRITERIA ...................................................................................................30 
 
3.3 
DONOR INCLUSION CRITERIA ........................................................................................................31 
 
3.4 
PREMATURE DISCONTINUATION OF STUDY THERAPY..................................................................31 
 
3.4.1 
Reasons for Premature Discontinuation of Study Therapy........................................................... 31 
 
3.4.2 
Follow-up for Participants Prematurely Discontinued from Study Therapy................................. 32 
 
3.5 
PREMATURE TERMINATION FROM THE STUDY............................................................................33 
 
3.5.1 
Reasons for Premature Termination from the Study....................................................................33 
 
3.5.2 
Follow-up for Participants Prematurely Terminated from the Study .......................................... 33 
 
4 
STUDY MEDICATIONS AND PROCEDURES......................................................................................33 
 
4.1 
OVERVIEW OF CONDITIONING AND POST TRANSPLANT REGIMEN..............................................33 
 8 


 
 
4.2 
DONOR BONE MARROW HARVEST AND NEPHRECTOMY..............................................................33 
 
4.3 
LEUKAPHERESIS ............................................................................................................................34 
 
4.4 
CONDITIONING REGIMEN..............................................................................................................34 
 
4.4.1 
Rituximab (Days –7, –2, 5, and 12)............................................................................................... 34 
 
4.4.2 
Low dose Total Body Iradiation (Days –5 and –4) ........................................................................ 35 
 
4.4.3 
MEDI-507 (Days –2, -1, 0, and 1).................................................................................................. 35 
 
4.4.4 
Thymic Irradiation (Day -1)………………………………………………………………………………………………………. 36 
 
4.4.5 
Tacrolimus Administration and Dosing (Day –1)........................................................................... 36 
 
4.4.6 
Prednisone (Days 4–20, 22–42) and Methylprednisolone (Days 22–42) ..................................... 37 
 
4.4.7 
ATG Administration in the event of Engraftment Syndrome………..........................…………………….37 
 
4.4.8 
Immunosuppression Withdrawal ................................................................................................. 37 
 
4.5 
TRANSPLANT PROCEDURES ..........................................................................................................39 
 
4.5.1 
Bone Marrow Transplant (Day 0) ................................................................................................. 39 
 
4.5.2 
Renal Transplant (Day 0) .............................................................................................................. 39 
 
4.6 
PROPHYLAXIS AGAINST AND TREATMENT OF INFECTION.............................................................40 
 
4.6.1 
Pneumocystis and Urinary Tract Infections.................................................................................. 40 
 
4.6.2 
Fungal and Yeast Infections ......................................................................................................... 40 
 
4.6.3 
CMV Infection .............................................................................................................................. 40 
 
4.6.4 
Herpes Infection ........................................................................................................................... 42 
 
4.7 
ASSESSMENT OF ALLOGRAFT DYSFUNCTION AND TREATMENT OF RENAL REJECTION................42 
 
4.7.1 
Definition of Allograft Dysfunction and Indication for Biopsy...................................................... 42 
 
4.7.2 
Diagnosis, Grading and Monitoring of Rejection.......................................................................... 42 
 
4.7.3 
Treatment of Rejection ................................................................................................................ 42 
 
4.8 
PROHIBITED MEDICATIONS...........................................................................................................43 
 9 


 
 
4.9 
DRUG ACCOUNTABILITY ..............................................................................................................43 
 
5. 
STUDY PROCEDURES..................................................................................................................... 43 
 
5.1 
GENERAL ASSESSMENTS...............................................................................................................43 
 
5.2 
LABORATORY ASSESSMENTS.........................................................................................................44 
 
5.3 
RENAL BIOPSY ...............................................................................................................................45 
 
5.3.1 
Renal Core Biopsy..........................................................................................................................45 
 
5.3.2 
Intraoperative Wedge Biopsy ...................................................................................................... 45 
 
5.3.3 
For-Cause Kidney Biopsy .............................................................................................................. 45 
 
6 
ADVERSE EVENTS.......................................................................................................................... 45 
 
6.1 
OVERVIEW .....................................................................................................................................45 
 
6.2 
DEFINITIONS .................................................................................................................................45 
 
6.2.1 
Adverse Event .............................................................................................................................. 45 
 
6.2.2 
Serious Adverse Event ................................................................................................................. 46 
 
6.2.3 
Unexpected Adverse Event .......................................................................................................... 46 
 
6.3 
COLLECTING ADVERSE EVENTS......................................................................................................46 
 
6.4 
GRADING, ATTRIBUTION AND REPORTING OF ADVERSE EVENTS ................................................47 
 
6.4.1 
Grading Criteria............................................................................................................................. 47 
 
6.4.2 
Attribution Definitions ................................................................................................................. 48 
 
6.4.3 
Adverse Event Reporting Requirements ......................................................................................48 
 
7 
STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN ............................................................. 48 
 
7.1 
ANALYSIS SAMPLES.......................................................................................................................48 
 
8 
QUALITY CONTROL AND QUALITY ASSURANCE.......................................................................... 48 
 
9 
ETHICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL PRACTICE..................... 49 
 
9.1 
STATEMENT OF COMPLIANCE ....................................................................................................48 
 10 


 
 
9.2 
INFORMED CONSENT...................................................................................................................49 
 
9.3 
PRIVACY AND CONFIDENTIALITY ...................................................................................................49 
 
REFERENCES .............................................................................................................................................. 50 
 
 
List of Appendices 
 
Appendix 1. Diagnosis and Classification of Selected Opportunistic Infections ........................................53 
 
Appendix 2. Current Banff Classification of Renal Allograft Pathology (Banff 2005) ....………………………….54 
 
Appendix 3. Staging and Grading of Graft-Versus-Host Disease ............................................................... 56 
 
Appendix 4. Donor Evaluations ..................................................................................................................57 
 
Appendix 5 MEDI-507 Dose Preparation Instructions .............................................................................. 59 
 
Appendix 6. Long Term Patient Follow-Up…………………………………………………………………………………….………60 
 
Appendix 7: Schedule of Events for Safety Follow-up…………………………………………………………………………….70 
 
 
List of Tables 
 
Table 1. Patient summaries for all CKBMT Trials………………………………………………………………………….………..19 
 
Table 2. Dosing nomogram for treatment of CMV infection .................................................................... 41 
 
Table 3. Attribution of adverse events ...................................................................................................... 48 
 
 
List of Figures 
 
Figure 1.  Long Term Results of Kidney Transplantation............................................................................ 13 
 
Figure 2. Conditioning Regimen ................................................................................................................ 14 
 
Figure 3.  Conditioning Regimens for Previous Clinical Trials……………………………………………….…………….... 17 
 
Figure 4.   Clinical Course…………………………………………………………………………………………………………………..…..20 
 
 
 
 
 
 11 


 
  1. 
BACKGROUND 
  
1.1 
SUMMARY 
  
Risk of long-term immunosuppression 
         Since the first successful human kidney transplantation by Murray et al. in 1956 1, 
numerous immunosuppressive regimens have been developed for clinical application.  As these 
more efficacious immunosuppressive drug combinations have successfully prevented or treated 
acute allograft rejection, short-term survival of organ transplants has significantly improved, 
resulting in solid organ transplantation becoming the therapy of choice for many end-stage 
organ diseases 2,3.  
          However, chronic use of immunosuppressive drugs results in significantly increased risks 
of cardiovascular disease 4-6, infection 7-9 and malignancies 10-13. Immunosuppressive 
medications also cause various side effects, such as nephrotoxicity, de novo diabetes 14-16, 
dyslipidemia 17-20 and neurotoxicity 21,22. Cardiovascular disease has become the most common 
cause of mortality, accounting for 30-48% of the deaths after kidney transplantation 10. 
Infection is also a common complication and remains the second most common cause of 
mortality after transplantation 7-9. The risk of many common cancers has been observed to be 
higher in chronically immunosuppressed transplant patients. Such risk is particularly high in 
non-melanoma skin cancer and melanoma/leukemia, which are 30 and 3-fold higher than that 
in the general population, respectively11,23. Some studies report that the overall incidence of 
cancer after kidney transplantation is as high as 40% after 20 years of immunosuppressive 
therapy, in contrast to a 6% cumulative risk for cancer in an age- matched, non-transplanted 
control population 13,24. Because of these morbidities, death with a functioning graft accounts 
for 16% of graft losses over the first 10 years after kidney transplantation 25. Chronic 
nephrotoxicity from calcineurin inhibitor (CNI) treatment is also a serious side effect 
Unfortunately, despite these toxicities that accompany the potent immunomodulatory effects 
of current therapeutic protocols, development of chronic rejection is not consistently 
prevented.  Approximately 15-30% (dependent upon the assay utilized) of renal transplant 
recipients receiving maintenance immunosuppression eventually develop anti-HLA antibodies 
27. Chronic rejection, often in association with de novo alloantibody detection, accounts for 
about 20% of graft losses by 10 years after kidney transplantation 25. In summary, the net effect 
of these limitations of currently available chronic immunosuppression protocols is an 
inexorable loss of previously functioning transplanted kidneys at an annual rate of about 5-7% 
28 and minimal improvement of renal graft half life in the last 10 years 2,3,29 (Fig. 1) 
 
 
 
 
 
 12 


 
Figure 1. Long Term Results of Kidney Transplantation 
Rationale of tolerance induction 
           Induction of tolerance has been considered one strategy to improve the long-term results 
of organ transplantation. Operational tolerance (defined as the absence of a destructive 
immune response to a transplanted tissue without ongoing immunosuppression) is very rare in 
kidney transplant recipients. These observations have emphasized that additional conditioning 
or treatment is required for consistent induction of tolerance across major histocompatibility 
complex (MHC) barriers. In order to justify clinical application, development of such additional 
conditioning / treatment regimens must utilize approaches with short and long-term risks that 
do not outweigh the benefits over current standard of care.  Presumably, if tolerance could be 
induced consistently, chronic rejection would be eliminated and the risks of cardiovascular 
disease, infection, malignancy and other drug-related complications should be considerably 
minimized.  These advantages must be balanced against the potentially increased risks of 
infection and treatment-related morbidities in the early post-transplant period, which may be 
higher after administration of the conditioning regimens required for tolerance induction.  
Tolerance induction via the mixed chimerism approach 
 
          Evidence that tolerance of kidneys can be induced via bone marrow bone marrow 
transplantation in humans is illustrated by the fact that recipients of successful allogeneic 
bone marrow transplants who subsequently suffer end-stage renal disease have undergone 
kidney transplantation from the same donor without the need for immunosuppressive 
therapy. However, myeloablative conditioning for full allogeneic bone marrow 
transplantation, specifically for the induction of tolerance of the kidney allograft, is neither 
necessary nor desirable. Nonmyeloablative conditioning regimens have been shown to result 
 13 


 
in mixed chimerism and donor-specific immunologic tolerance in a number of rodent model 
systems, 32,33 in miniature swine, 34 and in fully mismatched cynomolgus monkeys. 35-37   Our 
group has reported the successful induction of tolerance in patients with advanced multiple 
myeloma and renal failure through simultaneous bone marrow and renal transplantation from 
HLA matched donors (ITN study NKD01).38,39   More recently, we have reported tolerance 
induction in patients with end-stage renal disease (ESRD) without myeloma who received 
haploidentical kidney and bone marrow transplants (ITN study NKD03)40.  The originally 
studied protocol was revised (ITN036) to add rituximab and a short course of steroids and 
postoperative cyclosporine was replaced with tacrolimus to address the limitations of  
“engraftment syndrome” and development of donor specific antibody (DSA) observed in 
protocol (NKD03).  Although recipients treated with ITN036 did not develop DSA or humoral 
rejection, “engraftment syndrome” continued to be observed. The goal of this study is to 
develop a nonmyeloablative regimen that can induce comparable levels of transient mixed 
chimerism without “engraftment syndrome”.  The proposed conditioning regimen is depicted 
in Figure 2. Comparison with Figure 3 emphasizes that the only significant change from our 
most recently used conditioning is the substitution of TBI for cyclophosphamide on days -5 
and -4. Our conditioning regimen in NHPs has always utilized TBI (100-150 cGy on days -5 and 
-4), with which the majority of recipients develop mixed chimerism and survive long-term 
without evidence of engraftment syndrome or allograft rejection Nevertheless, 
cyclophosphamide had been selected for the initial clinical trials because, at that time, there 
was more extensive experience with this approach in human BM recipients. If the creatinine 
begins to rise or the level of donor chimerism falls by > 50% during the 2nd post-transplant 
week, Prograf will be discontinued and ATG will be administered (up to 5 doses over 10 days). 
Prograf administration will be resumed after ATG is discontinued. This addresses our 
observation of apparent synergistic CNI nephrotoxicity with that of engraftment syndrome 
(See below: Clinical studies). 
 
Figure 2. Conditioning regimen 
 
 
1.5 
 14 


 
1.2 
PRECLINICAL AND CLINICAL  STUDIES 
 
1.2.1 
Preclinical Studies  
 
We have previously demonstrated that the establishment of allogeneic mixed chimerism (i.e., 
survival of both host and donor lymphohematopoietic elements) with a nonmyeloablative 
conditioning regimen across MHC barriers can successfully achieve transplantation tolerance 
while otherwise maintaining full immunocompetence in mice, 41,42  in miniature swine, 34 and 
in fully mismatched cynomolgus monkeys. 35-37   Studies of the mechanism of tolerance 
induced by mixed chimerism have been carried out most extensively in mice, and have 
demonstrated that tolerance is induced centrally through a deletional mechanism, as 
established by analyses of T-cell receptor utilization. 43  Despite the more extensive 
mechanistic studies we have carried out in mice and miniature swine, we shall confine the 
preclinical data summarized here to our studies in cynomolgus monkeys, as these animals are 
most relevant to the present protocol. 
 
The initially successful nonmyeloablative conditioning regimen developed for induction of 
mixed chimerism and renal allograft tolerance in MHC fully mismatched cynomolgus 
monkeys35 consisted of total body irradiation (TBI), thymic irradiation (TI) and antithymocyte 
globulin. Splenectomy, bone marrow transplantation, and renal transplantation were 
performed on day 0 and cyclosporine was administered on days 0–28. Of 13 recipient 
monkeys undergoing this conditioning, 11 developed mixed chimerism and 10 survived long-
term without allograft rejection. 35,36,44   In these long-term survivors, alloantibody and 
chronic vasculopathy were detected in only 1 monkey that had not developed clear 
macrochimerism. Furthermore, all long-term survivors showed donor-specific 
unresponsiveness in mixed lymphocyte response (MLR) assays35  The longest surviving 
tolerant monkey was observed for more than 13 years post transplant, with a serum 
creatinine of 1.2 mg/dL and a BUN of 19 mg/dL; a renal biopsy at 10 years post transplant 
showed no diagnostic abnormalities, indicating that this protocol appears to not only avoid 
acute rejection but to prevent chronic rejection, which is the major cause for loss of long-
term renal allografts.  To our knowledge, of all published protocols leading to long-term 
survival of renal allografts in nonhuman primates, this mixed chimerism approach is the only 
one which avoids chronic rejection. Several modifications of our regimen utilizing either 
reduced doses of TBI, no TI, or no cyclosporine failed to induce chimerism, and all allografts 
were rejected; elimination of the splenectomy did not prevent the development of 
chimerism in all animals but resulted in graft loss.35 
On the basis of further murine studies in our research center, 43,45 additional studies in 7 
cynomolgus monkeys evaluated several modifications to the original protocol. The addition of 
costimulatory blockade with anti-CD40L antibody improved the reliability of engraftment and 
tolerance induction without the requirement for splenectomy 37. Five monkeys received anti-
CD40L added to the original regimen, including cyclosporine but without splenectomy, all 
developed chimerism, and none developed anti-donor antibodies. Of these five monkeys, one 
died due to a urethral stone on day 204, without evidence of allograft rejection, and one 
developed hemolytic uremic syndrome of unexplained origin; the other three monkeys 
remained stable without evidence of rejection for more than 8 years. These data suggested 
that improvement in T-cell depletion, with anti-CD40L as used in this study, could improve the 
reliability of engraftment and tolerance induction without the need for splenectomy.  
 15 


 
Most importantly, our pre-clinical studies indicated that induction of transient mixed 
chimerism is sufficient to induce tolerance of MHC fully mismatched renal allograft. Because 
chimerism has always been transient, no GVHD has been observed in these monkeys. The 
recipients treated with TBI-based conditioning regimen lost their chimerism more slowly than 
humans treated with cyclophosphamide-based conditioning regimen, no “engraftment 
syndrome” or acute kidney injury have been observed in our monkeys.  
 
 
1.2.2 
Clinical Studies:  Prior Studies 
 
Introduction: 
          Since the seminal work reported by Billingham, Brent and Medawar on neonatal tolerance 
in 1956, numerous tolerance induction strategies have been identified in rodents. However, 
only a very limited number of these have been successfully translated to large animals and even 
fewer to primates. Among the few protocols that have been applied in humans, induction of 
donor chimerism, either transient or permanent, currently appears to be the most promising 
strategy to achieve renal allograft tolerance. Initial results of clinical trials for tolerance 
induction in three centers have so far been reported.  Using TLI and DBMT, the Stanford group 
reported successful induction of stable chimerism and renal allograft tolerance but only in HLA 
identical kidney transplant recipients.46,47  More recently, Leventhal et al. at Northwestern have 
reported use of an intensive conditioning regimen and donor hematopoietic stem cells for 
induction of tolerance in HLA-mismatched kidney transplant recipients 48.  Although the follow-
up is still brief, persistent donor chimerism without GVHD has been reported, allowing weaning 
from all maintenance immunosuppression by 1 year in approximately half of their patients.   
         At Massachusetts General Hospital, based on decades-long basic studies in animal models 
32,35,37,49, we have applied combined kidney and donor bone marrow transplantation (CKBMT) 
for induction of allograft tolerance in both HLA matched and mismatched kidney transplant 
recipients 38,39,50. The early results of the initial five mismatched patients who underwent 
CKBMT have been reported 40. We subsequently extended this approach with a revised regimen 
to five additional patients. We have submitted for publication our observations in this later 
cohort as well as the longer-term follow-up (up to 10 years) of the previous recipients of HLA 
mismatched CKBMT (attached as Appendix 6 and briefly summarized here). 
 
The three preparative conditioning regimens are depicted in Figure 3.  The initial (NKD03) 
protocol was modified after treatment of the third subject who developed irreversible antibody 
mediated rejection, to include 1) administration of Rituximab, 375 mg/m²/dose on days -7 and -
2; and 2) administration of prednisone, 2 mg/kg/d starting on the day of transplantation and 
then tapering over the next 10 post-transplant days (modified NKD03). Since subjects treated 
with this modified NKD03 still developed donor specific antibodies (DSA) after discontinuation 
of immunosuppression, the regimen was further modified (ITN036) to add two more doses of 
Rituximab (375 mg/m²/dose on post-transplant days 5 and 12, more prolonged administration 
of prednisone until day 20, and tacrolimus in place of CyA for the 5 most recently treated 
subjects. A total of 10 subjects, age 22-46, 6 males and 4 females, were enrolled into these 
studies (Table 2).   
 16 


 
Donors were all HLA one haplotype mismatched parents or siblings. The first three subjects 
received the NKD03 regimen, the next two subjects received the revised NKD03 regimen. The 
last five subjects received the ITN036 conditioning. All patients developed transient 
multilineage mixed chimerism which became undetectable by 2-3 weeks post-CKBMT 40,51. All 
subjects except for Subject #1 developed cytokine syndrome-like manifestations 40,52.  This 
syndrome has been temporally associated with the loss of peripheral chimerism as well as of 
the return of host-derived elements. The most concerning manifestation of this syndrome is 
acute kidney injury (AKI), which was observed after day 10 in all patients except for Subject #1. 
The biopsies taken during AKI showed severe endothelial injury with CD8+ T cell infiltration, as 
reported in detail52. The peak of serum creatinine levels ranged from 3.5 to 15.4 during days 10-
20. Among nine subjects who developed AKI, three recovered without additional treatment, 
two with Thymoglobulin and plasma exchange, one with Thymoglobulin alone and one with 
steroid pulse. Two kidney allografts failed to recover despite treatments due to associated 
humoral rejection and thrombotic micro-angiopathy. 
 
 
Clinical courses of all subjects are depicted in Figure 4. 
 
Subject #1 was a 22 y.o. female who has continued to be well with normal kidney allograft 
function without ongoing immunosuppressive therapy for more than 10 years. All four protocol 
Figure. 3 Conditioning Regimens for Previous Clinical Trials 
 17 


 
biopsies performed up to 8 years after CKBMT showed no evidence of rejection in light and 
electron microscopy. No DSA has been detected.   
Subject #2 was a 22 y.o. man in whom all immunosuppressive medications were tapered off by day 422. 
He remained stable until year 7 following immunosuppression withdrawal. At that point he was first 
noted to have increased urinary protein. Allograft biopsy revealed no rejection but recurrence of his 
original disease, MPGN type 1. Mycophenolate mofetil (MMF) monotherapy for recurrent MPGN was 
initiated after the 8th year. He is currently stable without further increment of proteinuria.  
Subject # 3 was known to have positive PRA (50%) but ADA was not detectable by ELISA 
preoperatively. This subject developed severe irreversible acute humoral rejection on day 10.   
The protocol was subsequently modified with more strict inclusion criteria (PRA pretransplant 
detection against any specificity became a contraindication) plus the addition of two doses of 
pre-transplant rituximab and post-transplant  prednisone up to day 10 (modified NKD03).    
Subject #4 was a 25 y.o. man whose Immunosuppression was tapered and completely discon-
tinued on day 244. This subject developed anti- HLA class II DSA, soon after complete 
discontinuation of immunosuppression. His five-year protocol biopsy revealed basement 
membrane duplication by electron microscopy with minimal interstitial fibrosis and no evidence 
of cellular or vascular rejection. Although his kidney allograft function has continued to be 
stable with serum creatinine of 1.6-1.9 mg/dl, he has recently developed mild proteinuria at 7 
years post-transplant, and treatment with IVIG and MMF therapy have been recommended.  
Subject #5 was a 46 y.o. male in whom immunosuppression was tapered and discontinued 
completely on day 272.  He remained stable for 5 years with no evidence of rejection or C4d 
deposition in either light or electron microscopy.  However, after suffering severe episodes of 
gout, his renal function became unstable with detection of DSA by ELISA at 6 years. Since DSA 
became positive with newly appeared C4d deposition in the biopsy, he received a short course 
of high dose IVIG (2g/kg) followed by rituximab. His in vitro CML and MLR assays have 
continued to show complete absence of anti-donor T cell responses. After these treatments, his 
renal function stablized with no evidence of chronic humoral rejection and C4d staining 
returned to negative in the subsequent biopsy. He is currently doing well without maintenance 
immunosuppression. 
Subject # 6 developed AKI after day 10 but recovered without additional treatment. His 
immunosuppression was slowly tapered and completely discontinued at 8 months after CKBMT. 
He is currently at 3.5 years after transplantation and has been well, without 
immunosuppression and with a serum creatinine level of 1.5 mg/dl. Biopsy showed no evidence 
of rejection by either light or electron microscopy.  
Subject # 7 had her immunosuppression tapered and completely stopped at 8 months. She is 
currently at 3 years and 4 months after CKBMT with normal kidney function (serum creatinine 
0.8 mg/dl) with no evidence of rejection or C4d staining in the 2 year protocol biopsy  
Subject # 8 developed AKI after day 10. The renal allograft biopsy on day 11 showed no 
rejection but endothelial injury. Another biopsy, performed on day 22 revealed intra-renal 
thrombotic microangiopathy, possibly due to tacrolimus toxicity. Tacrolimus was discontinued 
and three doses of anti-thymocyte globulin were administered with MMF. Despite these 
treatments, her kidney function did not recover and she was eventually returned to CAPD at 7 
months after transplantation.  
 18 


 
Subject #9 also developed transient AKI after day 10 and recovered without additional 
treatment. Her immunosuppression was discontinued at 8 months after transplantation. She is 
currently well at 3 years after CKBMT with normal kidney function (serum creatinine 1.0 mg/dl). 
The protocol biopsy at 2 years showed no evidence of rejection. No DSA has been detectable.  
Subject #10 developed AKI two weeks after CKBMT.  His kidney function gradually returned to 
normal by 2 months after transplantation and a 6-month protocol biopsy did not show 
rejection. His immunosuppression was completely discontinued at 8 months. At 9 months, he 
developed acute pyelonephritis of the kidney allograft with moderately elevated serum 
creatinine (2.2 from 1.6 mg/dl). This was treated with antibiotics and the kidney function 
recovered to base line levels. However, 3 weeks after the resolution of his UTI, he developed 
severe acute cellular rejection (BANFF 2B) with no C4d staining.  DSA has never been detectable 
by either ELISA or LUMINEX. He was treated with steroid pulses and anti-thymocyte globulin, 
following which his renal function improved but never fully recovered.  Although he remains 
well, his compromised kidney function suggests that gradual progression to ESRD is likely. 
 
Table 1. Patient summaries for all CKBMT Trials 
 
  
 
 
 
           
 
 
 
 
 
 
 
 
 
 
 
 
B cell depletion : Recovery of CD3-CD19+ cells in two subjects (Subjects #1 and #2) treated with 
the original NKD03 regimen was observed by days 50 and 100, respectively.  With two doses of 
pre-transplant rituximab (modified NKD03), depletion of CD3-CD19+ cells was extended to day 
150 (Subjects #4 and #5) but complete loss of CD3-CD19+ cells from the peripheral blood was 
not observed. In contrast, peripheral blood CD3-CD19+ cells were essentially undetectable for 6 
months in all five subjects treated with 4 doses of peritransplant rituximab (ITN036). Of note 
although DSA has been detected at least transiently in 4 of 5 NKD03, no DSA has been 
detectable in all ITN036 subjects. 
 
 
 19 


 
 
              
Despite the encouraging results of successful long-term tolerance induction in our initial clinical 
trials, the major obstacle to more wide-spread application of this approach is the “engraftment 
syndrome”.  AKI is a major manifestation of engraftment syndrome and has been observed at 
approximately day 10 in all subjects except for Subject #1. Subject#1 had been treated with 
immunosuppression for 10 years after her first transplantation (at age 12) before receiving 
CKBMT (at age 22), which may be the reason she was exempted from the engraftment 
syndrome.  This syndrome has been described previously following both autologous and 
allogeneic bone marrow transplantation, which has been associated with the recovery of either 
host or donor type  hematopoietic elements 26.  We note that the AKI of engraftment syndrome 
has never been observed in our MHC-mismatched monkey model, in which chimerism is also 
lost, but at a more gradual pace, usually over 2-3 months 9,10,27.  Our current interpretation of 
these findings is that the pre-transplant cyclophosphamide-based regimen chosen for the 
clinical trials 14, in contrast to the non-myeloablative total body irradiation used in the monkey 
preparative regimen 9,10,27,28, may be inadequately suppressive, allowing rapid homeostatic 
recovery of host memory T cells resulting in rapid rejection of the donor hematopoietic graft.  
Further supporting this hypothesis is the observation that AKI has also never been observed in 
our HLA-matched CKBMT recipients, in whom chimerism as in the NHP recipients typically 
disappears more slowly, over a period of 2-3 months 12,13.   
Figure 4  Clinical Course 
 20 


 
The proposed pilot protocol is planned to address the “engraftment syndrome” related AKI, 
which currently remains the only major obstacle to wider clinical application of this approach.  
 
1.3 
RISKS TO PARTICIPANTS 
 
1.3.1 
MEDI-507  
 
The following information for MEDI-507 was taken from the current investigator’s brochure. 
 
The safety profile of MEDI-507 is based on over 600 patients with psoriasis, 70 patients with GVHD or 
renal transplantation, and 29 patients with lymphoproliferative disorders. The most serious adverse 
events in patients treated with MEDI-507 are: 
• 
Infusion-related/cytokine-release syndrome 
• 
Infections 
• 
Secondary cancers 
 
The following adverse events have been observed in patients treated with MEDI-507, and may be 
potentially related to MEDI-507 therapy: 
 
Infusion-related/cytokine-release syndrome: Infusion-related reactions such as chills, pyrexia, and 
fatigue have been commonly seen in patients with cancer, GVHD and renal transplantation, and 
psoriasis. These events have been mild to moderate in severity, transient in nature, and have not 
recurred with rechallenge. Other associated events included nausea, vomiting, and hypotension. 
 
Infections: T-cell antibodies may be immunosuppressive. Prolonged immunosuppression may increase 
the risk of infection, including opportunistic infections. Infections were common in both the cancer and 
GVHD studies. Infections occurred in 3 (16%) of 19 patients in MI-CP099, with 5 patients (26%) having 
positive CMV antigen. Three patients discontinued treatment after testing positive for CMV (protocol-
specified reason for discontinuation of MEDI-507). In MI-CP107, there were two infection-associated 
SAEs (staphylococcal bacteremia and RSV infection) that occurred in 2 (20%) of 10 patients; both events 
were judged by the investigator as not being related to MEDI-507. In MI-CP042, infections occurred in 
16 of 17 patients and were a primary cause of death in 6 patients. The most common infectious agents 
were staphylococci followed by CMV. Three patients developed infections with Aspergillus or other 
mycelial fungi. A single patient experienced cryptosporidiosis involving the lung and colon. In MI-CP046, 
infections were common in both MEDI-507 (19 [90%]) and placebo (12 [92%]) patients and the most 
common site of infection was blood. The most common isolates were the same among MEDI-507 and 
placebo patients, and included staphylococcus species, CMV and enterococcus. The incidence of fungal 
infections (primarily Candida) was higher in the pooled placebo group (7/13, 54%) than among MEDI-
507 patients (4/21, 19%). In MI-CP049, infections were seen in 3 of 10 patients (30%). 
 
Secondary cancers: Prolonged and sustained immunosuppression may result in an increased risk of 
developing certain types of cancer. 
 
EBV-associated LPD, PTLD, and lymphoma have occurred in clinical trials of MEDI-507. In the two cancer 
trials of MEDI-507 (MI-CP099 and MI-CP107), EBV-LPD has been reported in five patients including two 
patients with LGL and one patient each with CTCL, peripheral T-cell lymphoma (PTCL), and ATL. Most of 
these patients (4 of 5) who developed EBV-LPD received ≥ 3.4 mg/kg/dose MEDI-507, and all cases were 
 21 


 
j u d g e d as h a vi n g eit h er a p ossi bl e r el ati o ns hi p ( 2 of 5 p ati e nts) or pr o b a bl e r el ati o ns hi p ( 3 of 5 p ati e nts) 
t o M E DI-5 0 7. O n e p ati e nt wit h L GL d ev el o p e d a s ec o n d ar y l e u k e mi a ( M 4  ty p e l e u k e mi a) 1 y e ar aft er 
c o m pl eti n g M E DI-5 0 7 t h er a py. T h e e v e nt w as gr a d e 5 (f at al) a n d j u d g e d as r e m ot el y r el at e d t o M E DI -
5 0 7 tr e at m e nt.  
 
I n t h e G V H D st u di es of M E DI-5 0 7 (st u di es MI -C P 0 4 2 a n d MI -C P 0 4 9 i n T a bl e 3), E B V -L P D a n d P TL D h av e 
b e e n r e p ort e d i n o n e p ati e nt e ac h, a n d E B V -l y m p h o m a h as b e e n r e p ort e d i n t w o p ati e nts. A c as e of 
A ML r el a ps e h as als o b e e n r e p ort e d.  
 
I n t h e st u dy of r e n al tr a ns pl a nt p ati e nts, o n e p ati e nt ex p eri e nc e d a b as al c ell c arci n o m a of t h e ski n o n 
a n ar e a of acti nic ex p os ur e r e p o rt e d d uri n g l o n g-t er m f oll o w-u p. T w o p ati e nts i n t h e ps ori asis st u di es 
h a d s ec o n d ary m ali g n a nci es (s q u a m o us c ell c arci n o m a of t h e s ki n a n d M D S) f oll o wi n g tr e at m e nt wit h 
M E DI -5 0 7. B ot h p ati e nts h a d a pri or hist ory of t h es e r es p ectiv e c o n diti o ns, a n d w er e e nt er e d i nt o a 
M E DI -5 0 7 ps ori asis st u dy i n vi ol ati o n of pr ot oc ol e ntry crit eri a t h at excl u d e d p ati e nts wit h a hist ory of 
c a nc er ( alt h o u g h i n t h e l att er c as e, t h e c o n diti o n w as n ot discl os e d at st u dy e nr oll m e nt).  
 
T hr e e c as es of P TL D h a v e b e e n r e p ort e d i n i nv esti g at or -i niti at e d a n d c o m p assi o n at e us e st u di es of 
M E DI -5 0 7.  
 
1. 3. 2  
Rit u xi m a b  ( Rit u x a n ®)  
 
T h e f oll o wi n g i nf or m ati o n f or rit uxi m a b w as t a k e n fr o m t h e Rit ux a n p ac k a g e i ns ert.  
 
I n dic ati o ns f or us e: Rit ux a n ( Bi o g e n I d ec I nc. a n d G e n e nt ec h U S A, I nc., S o ut h S a n Fr a ncisc o, C A) is a 
C D 2 0 -dir ect e d cyt ol ytic a nti b o dy i n dic at e d f or t h e tr e at m e nt of t h e f oll o wi n g:  
 
•  
N o n -H o d g ki n’s ly m p h o m a ( N HL).  
•  
R h e u m at oi d art hritis ( R A) i n c o m bi n ati o n wit h m et h otr ex at e i n a d ult p ati e nts wit h m o d er at el y - 
t o s e v er ely-activ e R A w h o h a v e i n a d e q u at e r es p o ns e t o o n e or m or e T N F a nt a g o nist t h er a pi es.  
 
C o m m o n a dv ers e ev e nts:  
 
•  
N HL ( 2 5 %): i nf usi o n r e acti o ns, f ev er, l y m p h o p e ni a, c hills, i nf ecti o n a n d ast h e ni a.  
•  
R A ( 5 %): hy p ert e nsi o n, n a us e a, u p p er r es pir at or y tr act i nf ecti o n, art hr al gi a, pr uri t us, a n d 
pyr exi a. Ot h er i m p ort a nt a dv ers e r e acti o ns i ncl u d e i nf usi o n r e acti o ns, s eri o us i nf ecti o ns, a n d 
c ar di o v asc ul ar ev e nts. 
 
S eri o us a dv ers e ev e nts:  
 
T h e f oll o wi n g s eri o us a dv ers e ev e nts h a v e b e e n ass oci at e d wit h us e of Rit ux a n:  
 
•  
T u m or l ysis sy n dr o m e  
•  
S e v er e m uc oc ut a n e o us r e acti o ns  
•  
P ML  
•  
H e p atitis B r e acti v ati o n wit h f ul mi n a nt h e p atitis  
•  
C ar di ac arr hyt h mi as a n d a n gi n a  
•  
B o w el o bstr ucti o n a n d p erf or ati o n  
 
2 2  


 
 
For additional information, please refer to the package insert at the following web site: 
 
http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf 
 
Note: Most of the serious adverse events were related to tumor lysis in the treatment of cancer and are 
therefore not thought to be relevant to the current protocol. 
 
1.3.3 
Low Dose Total Body Irradiation   
 
Low dose TBI may cause bone marrow suppression, immune suppression, nausea, vomiting. There is a 
possibility that TBI with or without other anti-lymphocyte therapy may lead to a malignancy months or 
years following the transplant. Epidemiologic studies have established that low dose TBI (250 300 
cGy) increases the life-time risk of malignancy by a factor of 1.2 over that observed in individuals 
without prior exposure to irradiation (33). In contrast, as described above, long-term 
immunosuppression is associated with a 2-30 fold increased risk of cancer (13, 24). Such data would 
appear to justify the use of low dose irradiation for tolerance induction.  
 
Because of the risk of genetic damage, all women of childbearing years will have a pregnancy test 
before starting the treatment. Although reproductive organs will be shielded, TBI may also result in 
sterility, cause genetic damage to future offspring, or interfere in normal wound healing.  
 
1.3.4 
Thymic  Irradiation  
 
Irradiation of the thymus gland may cause nausea, vomiting, mild skin irritation and inflammation of the 
esophagus (causing mild, temporary dysphagia). Occasionally, pericarditis or pneumonitis may occur. 
Hypothyroidism and secondary malignancies are additional potential risks. 
 
There is a risk of multi-organ failure, including cardiac, renal, pulmonary, CNS, and hepatic failure. This 
risk is increased in patients who have already had significant chemotherapy or radiation therapy or both. 
These risks may be life threatening and lead to fatal complications. 
 
There is a possibility that the chemotherapy with or without radiation therapy may lead to a malignancy 
months or years following the transplant. Because of the risk of genetic damage, all women of 
childbearing years will have a pregnancy test before starting the treatment. 
 
1.3.5 
Tacrolimus  
 
Side effects of tacrolimus include renal insufficiency, abnormal liver function studies, seizures, nausea, 
vomiting, confusion, hypomagnesemia, tremulousness, and increased risk of secondary malignancies. 
Co-administration with methylprednisolone will decrease hepatic metabolism and thus increase 
tacrolimus levels; convulsions have been reported with concomitant high doses of methylprednisolone. 
Additional information about tacrolimus can be found in the package insert at 
http://www.astellas.us/docs/prograf.pdf 
 
1.3.6 
Prednisone   
 
 23 


 
Side effects of corticosteroids include convulsions, headache, vertigo, mood swings, psychosis, 
congestive heart failure (CHF), hypertension, Cushing syndrome, menstrual irregularities, hyperglycemia, 
GI irritation, peptic ulcer, weight gain. Dermatologic effects may include thin skin, petechiae, 
ecchymosis, facial erythema, poor wound healing, hirsutism, and urticaria. Muscle weakness, loss of 
muscle mass, and osteoporosis may also occur. Ophthalmologic complications may include increased 
intraocular pressure, glaucoma, exophthalmos, and cataracts. Other complications may include 
immunosuppression and increased susceptibility to infection. 
 
For further information about prednisone, see the package insert at  
http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=16633 
 
 
1.3.7 
GVHD  
 
Since induction of persistent chimerism is not expected with our nonmyeloablative regimen, the risk of 
GVHD is considered very low. No GVHD has been observed in 10 patients who received combined kidney 
and bone marrow transplantation from HLA-mismatched donors under a similar protocol (NKD03 and 
ITN 036; see section 1.2.2). 
  
The risk of GVHD increases depending on the severity of the conditioning regimen. In allogeneic bone 
marrow transplantation with meloablative conditioning, acute GVHD and/or chronic GVHD are common 
complications (30-90% acute GVHD risk depending on the degree of HLA match and subject age group; 
30%–50% chronic GVHD risk with conventional transplants). In our series of patients  with neoplastic 
conditions receiving HLA-identical nonmyeloablative bone marrow transplants, the risk of GVHD in the 
absence of DLI has been approximately 30%, and with only a few exceptions, has been grade II GVHD 
confined to the skin. In recipients of a single DLI on day 35, the risk of acute GVHD has been 
approximately 40% (4 of 10 patients), and three of these have also been grade II GVHD of the skin, with 
or without the subsequent development of chronic GVHD. In 37 HLA-identical transplants using an ATG-
containing regimen, we observed a 30% incidence of grade II or more acute GVHD overall. As noted in 
section 1.2.2, no GVHD was observed in ten non-HLA- identical bone marrow transplant recipients after 
treatment with our MEDI-507-containing conditioning regimen. 
 
1.3.8 
Renal Graft Failure  
 
The 2010 Annual Report of the U.S. Scientific Registry of Transplant Recipients and the Organ 
Procurement and Transplantation Network estimates 1, 5 and 10-year graft survival rates for renal 
allograft recipients of living donor allografts as 97%, 80% and 60%, respectively, based on over 64,000 
transplants performed between 1998 and 2010. Thus, the short-term outcomes for living donor renal 
graft recipients using conventional treatment methods are excellent, but long-term results have not 
been satisfactory. Although 7/10 recipients who received previous regimens are doing well with the longest 
survival exceeding 10 years, the outcomes for the experimental intervention described in this protocol 
are unknown. 
 
1.3.9   Infection  
 
While it is recognized that the transient pancytopenia and temporary T-cell depletion induced by 
conditioning for BMT under this protocol could theoretically lead to an increased risk of infection post 
transplant, our experience to date (with over 200 primate renal allografts performed with a similar type 
 24 


 
of protocol, and with the 10 patients receiving a simultaneous kidney and marrow transplant at MGH) 
has been that infection is not a major problem. This probably reflects the high level of attentiveness to 
potential infectious complications among the surgical and BMT staff and the prophylactic antimicrobial 
treatments that are used. 
 
 1.3.10   Bone Marrow Transplant-related Mortality  
 
There was no bone marrow transplant mortality in 10 patients treated with combined kidney and bone 
marrow transplantation. Additionally, no patient mortality has also been seen in 10 myeloma recipients 
who received CKBMT with similar conditioning regimen. {Spitzer, 1999 #42} {Spitzer, 2011 #3568} 
 
1.3.11   Renal  Biopsies  
 
A wedge biopsy is performed on the day of transplant. Complications for the wedge biopsy include 
hemorrhage, renal infarction, infection, retention cysts, urine fistula, and hydronephrosis. All 
subsequent biopsies are performed percutaneously under ultrasound guidance with an 18-gauge 
needle.  The biopsy will be performed only in patients with platelet counts >50,000. The most frequent 
complication of temporary, self-limited bleeding occurs in approximately 2% of allograft recipients at 
the MGH.  
 
There has been no significant allograft dysfunction or loss of an allograft due to a biopsy in over 500 
consecutive patients. The procedure is performed in the out-patient radiology suite, and the patient is 
monitored for stability in the transplant unit for approximately 8 hours prior to discharge on the evening 
of the biopsy. In the case of a rare but significant bleeding event resulting from the renal biopsy, 
transfusion with packed red blood cells may or may not become medically necessary. 
 
1.3.12   Leukapheresis  
 
Leukapheresis will be performed on the recipient prior to initiating the conditioning regimen and these 
cells will be frozen. In the unlikely event that the recipient develops GvHD, we will give the 
leukapheresis product to the participant (intravenous infusion), to treat the GvHD. If the participant 
does not develop GvHD, the leukapheresis product will be used for in vitro studies. Complications that 
may occur during leukapheresis include changes (increase or decrease) in blood pressure or pulse, 
bleeding, or hypocalcemia. Bleeding, fever, and infection from leukapheresis can also occasionally occur. 
On rare occasions, these complications may be life-threatening. 
 
1.3.13   Engraftment Syndrome  
 
Engraftment syndrome was observed in nine of the 10 patients in NKD03/ITN036. This syndrome, which 
is associated with the loss of chimerism and hematopoietic recovery of the recipient   (typically during 
the second week after bone marrow administration), is characterized by fever, fluid retention, and renal 
dysfunction., all of which respond to steroids and are reversible. Acute kidney injury (AKI) is a major 
manifestation of engraftment syndrome and has been observed at approximately day 10 in all subjects 
except for Subject #1.  This syndrome has been described previously following both autologous and 
allogeneic bone marrow transplantation, which has been associated with the recovery of either host or 
donor type  hematopoietic elements 27.  We note that the AKI of engraftment syndrome has never been 
observed in our MHC-mismatched monkey model, in which chimerism is also lost, but at a more gradual 
pace, usually over 2-3 months.9,10,28  Our current interpretation of these findings is that the pre-
 25 


 
transplant cyclophosphamide-based regimen chosen for the clinical trials,15  in contrast to the non-
myeloablative total body irradiation used in the monkey preparative regimen,9,10,28,29  may allow 
rapid homeostatic recovery of host memory T cells, which may be associated with significant effector 
function, as suggested by the observation of CD8 T cell activation immediately following conditioning 16 
and rapid rejection of the donor hematopoietic graft.  Further supporting this hypothesis is the 
observation that AKI has also never been observed in our HLA-matched CKBMT recipients, in whom 
chimerism as in the NHP recipients typically disappears more slowly, over a periods of 2-3 months.  In 
this pilot trial, we expect that AKI can be prevented by inducing more stable chimerism (but still 
expected to be transient chimerism) by substituting low dose TBI for cyclopshophamide. 
 
1.3.14 ATG (Thymoglobulin or ATGAM) 
 
The most common adverse events associated with ATG are:  
• 
Moderate fever and chills  
• 
Leukopenia  
• 
Although rare, the most common severe events associated with ATG are:  
o Allergic or anaphylactoid reactions  
o Serum sickness or serum sickness-like symptoms (fever, pruritus and rash associated with 
arthralgia or myalgia)  
 
As with all immunosuppression, administration of ATG may be associated with an increased risk of 
infection and the development of malignancy (especially of the skin and lymphoid system). 
Thymoglobulin (1.5 mg/kg/day × 3–7 days) the course can be extended in the case of delayed graft 
function) is standard induction immunosuppression for both cadaveric and living-donor renal 
transplants at many centers.  
 
The carcinogenic effects and the effect of ATG on fertility have not been established. ATG is 
contraindicated in patients with a history of allergy or anaphylaxis to rabbit proteins or to any product 
excipients, or who have active acute or chronic infections that contraindicate any additional 
immunosuppression.  
 
For additional information on the risks associated with ATG, refer to the package insert for 
Thymoglobulin® (Genzyme) at the following website: 
http://www.thymoglobulin.com/home/thymo_pdf_pi.pdf 
 
For additional information on the risks associated with ATGAM, refer to the package insert for Atgam® 
(Pfizer) at the following website:  
http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/license
dproductsblas/fractionatedplasmaproducts/ucm199603.pdf  
 
1.4 
RISKS TO DONORS 
 
1.4.1 
Bone Marrow  Donation  
 
Risks of bone marrow donation are related to either the administration of anesthesia or the operative 
procedure itself. Risks of anesthesia include, but are not limited to, postoperative nausea, vomiting, 
 26 


 
fatigue and rare life-threatening allergic reactions or hemodynamic instability. Most donors experience 
postoperative discomfort at the sites of bone marrow harvest. On average, the soreness and bruising 
last for approximately 2–3 weeks post harvest. A small percentage of donors (less than 10%) experience 
prolonged (weeks or months) pain or sciatic type pain, likely as the result of inflammation of the nerve 
roots from local bleeding or edema. Rare complications of bone marrow harvesting include local 
infection (including reports of osteomyelitis), pelvic fracture, phlegmon formation, pancreatitis, ileus, 
and fat embolism. Fatal complications following bone marrow harvesting are exceptionally rare and 
have been related to cardiopulmonary complications secondary to anesthesia or other catastrophic 
events, such as pulmonary embolism. 
 
1.4.2 
Kidney Donation  
 
Risks of kidney donation include the same anesthesia-related complications described above. The major 
postoperative morbidity associated with donor surgery includes pneumonia, wound infection, 
hematoma, phlebitis, pulmonary embolism, and urinary tract infection. The surgical complication rate 
for kidney donation is approximately 2%. The perioperative mortality for a living kidney donor is 
estimated to be 0.033%. Although uninephrectomy of living donors has been rarely associated with 
proteinuria and hypertension 6–10 years following nephrectomy, careful study of long-term outcome in 
kidney donors (up to 23 years) and army personnel who lost kidneys due to trauma during 
World War II (45 years’ follow-up) did not substantiate an increased risk of hypertension or renal failure 
with uninephrectomy. 
 
1.4.3 
Combined BMT and Kidney Donation  
 
The major risk to the donor for either nephrectomy or marrow procurement is that of general 
anesthesia. The simultaneous procurement of kidney and bone marrow requires approximately an 
additional hour of anesthesia as compared to a nephrectomy alone. 
 
 
1.5 
RATIONALE FOR SELECTION OF CONDITIONING REGIMEN 
All previously treated human subjects except for Subject #1 developed cytokine syndrome-like 
manifestations 40,52.  This syndrome has been temporally associated with the loss of peripheral 
chimerism as well as of the return of host-derived elements. The most concerning manifestation of this 
syndrome is acute kidney injury (AKI), which was observed after day 10 in all patients except for Subject 
#1. The biopsies taken during AKI showed severe endothelial injury with CD8+ T cell infiltration (Fig. 4), 
as reported previously in detail52. The peak of serum creatinine levels ranged from 3.5 to 15.4 during 
days 10-20. Among nine subjects who developed AKI, three recovered without additional treatment, 
two with Thymoglobulin and plasma exchange, one with Thymoglobulin alone and one with steroid 
pulse. Two kidney allografts failed to recover despite treatments due to associated humoral rejection 
and thrombotic micro-angiopathy. 
 
This syndrome has been described previously following both autologous and allogeneic bone marrow 
transplantation, which has been associated with the recovery of either host or donor type  
hematopoietic elements 26.  We note that the AKI of engraftment syndrome has never been observed 
in our MHC-mismatched monkey model, in which chimerism is also lost, but at a more gradual pace, 
usually over 2-3 months 9,10,27.  Our current interpretation of these findings is that the pre-transplant 
cyclophosphamide-based regimen chosen for the clinical trials 14, in contrast to the non-
myeloablative total body irradiation used in the monkey preparative regimen 9,10,27,28, may be 
 27 


 
inadequately suppressive, allowing rapid homeostatic recovery of host memory T cells resulting in 
rapid rejection of the donor hematopoietic graft.  Further supporting this hypothesis is the 
observation that AKI has also never been observed in our HLA-matched CKBMT recipients, in whom 
chimerism as in the NHP recipients typically disappears more slowly, over a periods of 2-3 months 
12,13.  We therefore propose to replace cyclophosphamide with low dose TBI in this clinical pilot study. 
 
 
2. 
STUDY DESIGN 
 
2.1 
DESCRIPTION 
 
This is a single center, pilot study of 2 adults with end stage renal disease and no evidence of prior 
sensitization, and their donors. 
 
Recipients will receive a conditioning regimen comprising rituximab, low dose whole body irradiation, 
MEDI-507 and thymic irradiation prior to combined renal and bone marrow transplant. A short 
postoperative course of steroids will be administered. Tacrolimus will be given for a defined period and 
then tapered if specific criteria are met. 
 
Prophylaxis will be provided for PCP, fungal/yeast infection, CMV, and perioperative infection. 
 
The proportion of participants without engraftment syndrome and successfully withdrawn from 
immunosuppression will be assessed. Clinical outcomes will be compared with measurements of donor-
specific tolerance and other immune parameters. 
 
Participants will be followed for a total of 5 years post CKBMT.  Assessments will be performed for 
participant and graft survival, and long-term adverse events. Participants who fail to complete 
immunosuppression withdrawal will be followed for 104 weeks (24 months) from the time they cease 
further reduction in immunosuppression. 
 
 
2.2 
CONSENT FOR PARTICIPATION 
 
For individuals identified as potential candidates for the trial, a consent addressing all aspects of the 
trial, including the planned withdrawal of immunosuppression will be obtained before any screening 
procedures are performed for evaluation of a participant’s eligibility for the trial. 
 
Informed consent will also be obtained from the donor and will be completed prior to performance of 
donor screening procedures.. 
 
2.3 
STUDY ENDPOINTS 
 
2.3.1 
Primary Endpoint  
 
The primary endpoint of this study is successful induction of transient chimerism and renal allograft 
tolerance without “engraftment syndrome” or “acute kidney injury”.  
 
 
 28 


 
2.4 
STOPPING RULES 
 
2.4.1 
Ongoing Review  
 
The Principal Investigator will review safety data. Enrollment of participants in the trial and withdrawal 
of immunosuppression in current trial participants will be suspended at any time if any of these reviews 
concludes that there are significant safety concerns. 
 
2.4.2 
Review of Specific Adverse  Events  
 
If the following events occur at any time during the study, they will be reviewed by the DMC. Any 
occurrence of death, graft loss, GVHD greater than grade II or prolonged neutropenia (> 14 Days) will 
result in suspension of enrollment pending DMC review. 
 
• 
Death of a participant. 
 
• 
Any malignancy (excluding basal cell carcinomas of the skin and CIS of the cervix) in two 
participants. 
 
• 
Renal graft loss or irreversible organ failure in any participant, as evidenced by a return to 
dialysis after 1 week post-transplant or a sustained serum creatinine >3 times that established at 
post-transplant baseline. See Section 4.7.1 for definition of baseline creatinine.   
 
• 
Humoral rejection in one participant. 
 
• 
Acute cellular rejection greater than or equal to grade IIB in two participants. 
 
• 
Acute GVHD greater than or equal to grade II in one participant. 
 
2.4.3 
Data Monitoring Committee  
 
The initial DMC meeting to review the study protocol will occur before the first patient receives CKBMT 
transplant. The review of participant data will occur 6 months after the first patient has received a 
transplant. Meetings will occur every 6 months thereafter. A DMC meeting will also occur if any of the 
specific adverse events in section 2.4.2 occur in enrolled participants.  
 
 
2.5 
ENROLLMENT, TIMING OF TRANSPLANT, AND LENGTH OF FOLLOW- UP 
 
For this study, enrollment is defined as the day on which the informed consent is signed.  
 
Participants who complete immunosuppression withdrawal will be followed for a total of 5 years post 
CKBMT.  additional Assessments will be performed for participant and graft survival and for long-term 
adverse events 
 
Participants who fail to complete immunosuppression withdrawal will be followed for 104 weeks (24 
months) from the time they cease further reduction in immunosuppression. 
 29 


 
 
3. 
ELIGIBILITY  
 
3.1 
RECIPIENT INCLUSION CRITERIA  
 
Patients who meet all of the following criteria are eligible for enrollment as study participants: 
 
1.   Male or female 18–60 years of age. 
 
2.   Candidate for a living-donor renal allograft with a one haplotype identical donor identified. 
 
3.   First or second transplant with either a living donor or cadaveric transplant as the first transplant. 
 
4.   Use of FDA-approved methods of contraception (those with less than a 3% failure rate) by all 
recipients from the time that study treatment begins until 104 weeks (24 months) after renal 
transplantation. (For further information on FDA-approved methods of contraception, see 
http://www.fda.gov/ForConsumers/ByAudience/ForWomen/ucm118465.htm 
 
5.   Ability to understand and provide informed consent. 
 
6.   Serologic evidence of prior exposure to EBV. 
 
 
3.2 
RECIPIENT EXCLUSION CRITERIA 
 
Patients who meet any of these criteria are not eligible for enrollment as study participants: 
 
1.   ABO blood group-incompatible renal allograft. 
 
2.   Evidence of anti-HLA antibody within 60 days prior to transplant as assessed by routine methodology 
(AGH and/or ELISA)  
 
3.   Leukopenia (WBC less than 2,000/mm3) or thrombocytopenia (platelet count <100,000/mm3). 
 
4.   Seropositivity for HIV-1, hepatitis B core antigen, or hepatitis C virus (confirmed by hepatitis 
C virus RNA); or positivity for hepatitis B surface antigen. 
 
5.   Cardiac ejection fraction ≤ 40% or clinical evidence of cardiac insufficiency. 
 
6.   Forced expiratory volume (FEV1) < 50% of predicted. 
 
7.   Lactation or pregnancy. 
 
8.   History of cancer other than basal cell carcinoma of the skin or carcinoma in situ of the cervix. 
 
9.   Underlying renal disease etiology with a high risk of disease recurrence in the transplanted kidney 
(such as focal segmental glomerulosclerosis, type I or II membranoprolifertive glomerulonephritis).  
 
 30 


 
10. Prior dose-limiting radiation therapy. 
 
11. Known genetic disease or family history that may result in greater sensitivity to the effects of 
irradiation, or a physical deformity that would preclude adequate shielding or appropriate dosing during 
the irradiation component of the conditioning regimen. 
 
12. Enrollment in other investigational drug studies within 30 days prior to enrollment. 
 
13. Abnormal (> 2 × lab normal) values for (a) liver function chemistries (ALT, AST, AP), (b) 
bilirubin, (c) coagulation studies (PT, PTT). 
 
14. Allergy or sensitivity to any component of MEDI-507, tacrolimus, or rituximab. 
 
15. Maintenance immunosuppression within 3 months prior to conditioning other than physiological 
doses of steroids, defined as ≤ 50 mg of hydrocortisone or dose equivalent. 
 
16.  The presence of any medical condition that the investigator deems incompatible with participation 
in the trial. 
 
3.3 
DONOR INCLUSION CRITERIA 
 
Donors who meet the following criteria will undergo nephrectomy and bone marrow aspiration under 
general anesthesia. Sufficient marrow will be obtained to provide at least 2 × 108 nucleated cells per 
kilogram weight of the recipient. 
 
1.   Male or female 18–65 years of age. 
 
2.   For females of childbearing potential: a serum pregnancy test showing negative results. 
 
3.   Excellent health per conventional predonor history (medical and psychosocial evaluation). 
 
4.   Acceptable laboratory parameters (hematology in normal or near-normal range; liver function 
<2 times the upper limit of normal, and normal creatinine). 
 
5.   Negative for viral infection with HbsAg, HIV, HCV, or HTLV-1. 
 
6.   Cardiac/pulmonary function within normal limits (CXR, ECG). 
 
7. Ability to understand and provide informed consent. 
 
8. Meets standard institutional criteria for both bone marrow and kidney donation 
 
 
3.4 
PREMATURE DISCONTINUATION OF STUDY THERAPY 
 
3.4.1 
Reasons for Premature Discontinuation of Study Therapy  
 
 31 


 
Study therapy is defined as initiation of any or all of the study medications or procedures described in 
section 5. 
 
Study therapy will be discontinued for the following reasons: 
 
• 
Hypersensitivity. If a participant develops a persistent hypersensitivity reaction to rituximab or 
MEDI-507 despite the measures described in sections 4.4.1, 4.4.1.2, 4.4.3.1 and 4.4.3.3 
 
• 
Adverse experience. If a participant suffers from an adverse experience that, in the judgment of 
the principal investigator presents an unacceptable consequence or risk to the participant. 
 
• 
Intercurrent illness or infection. If during the course of the study a participant develops an 
illness or infection that is not associated with the condition under study and that requires 
treatment not consistent with protocol requirements; or, if a participant develops an 
intercurrent illness that in the judgment of the principal investigator in any way justifies 
discontinuation. 
 
• 
Protocol violation. If a participant cannot comply with the study protocol, and the protocol 
deviations are sufficient to jeopardize his or her well-being or the integrity of the study. 
 
3.4.2 
Follow -up for Participants  Prematurely Discontinued  from  Study Therapy  
 
3.4.2.1   Safety Follow-up Assessments  
 
All enrolled participants who discontinue study therapy, regardless of outcome, will complete a safety 
follow-up. The following assessments will be performed at each safety follow-up visit: 
 
• 
Adverse events 
• 
Concomitant medications 
• 
Physical exam 
• 
Hematology 
• 
Serum and basic chemistries 
• 
Thyroid function 
• 
GVHD assessment 
• 
Graft survival 
• 
Chimerism  if still detectable at the previous visit 
 
3.4.2.2   Safety Follow-up Visit Schedule  
 
Participants who discontinue study therapy will observe this visit schedule: 
 
• 
A visit 2 weeks after discontinuation 
• 
A visit every 4 weeks for 24 weeks 
• 
A visit every 13 weeks for 78 weeks 
 
 
 32 


 
Participants in safety follow-up will have the option of scheduling a telephone visit in lieu of a clinic visit 
every other visit when the visits are 13 weeks apart. 
 
 
3.5      PREMATURE TERMINATION FROM THE STUDY 
 
3.5.1     Reasons for Premature Termination from the Study  
 
Participants will be prematurely terminated from the study for the following reasons: 
 
• 
Withdrawal of consent: If for any reason the participant withdraws consent during the study, 
the participant shall be terminated from the study. 
 
• 
Lost to follow-up: Participants who fail to return for visits and do not respond to repeated 
contact by the site staff are considered “lost to follow-up.” Realistic efforts will be made to 
locate these participants and ask them to continue in the study or to attend the study 
termination visit so that we may collect closeout study data. 
 
• 
Participants may only be replaced if they have been withdrawn from the study prior to receiving 
MEDI-507 and have had no study-related adverse events. 
 
3.5.2     Follow-up for Participants Prematurely Terminated from the Study  
 
Participants who wish to withdraw consent will be asked to complete the safety follow-up schedule 
specified in Section 3.4.2  
 
Participants who are prematurely terminated from the study during or after irradiation will be advised 
of the risk of cytopenias and will be advised to arrange to be followed, particularly during the 4-week 
period following irradiation. Every attempt will be made to provide this follow-up for safety reasons, 
even if the participant has withdrawn consent. 
 
4.   STUDY MEDICATIONS AND PROCEDURES 
 
4.1 
OVERVIEW OF CONDITIONING AND POST TRANSPLANT REGIMEN 
 
Participants will receive a conditioning regimen that starts with rituximab on days –7 ,–2, 5, and 12, 
TBI on days –5 and –4. MEDI-507 will be administered on days –2, –1, 0, and 1. Thymic irradiation 
will be given on day–1, and combined renal and bone marrow transplant will be done on day 0. 
Prednisone will be started at2 mg/kg on day 4 and tapered off by day 20. Tacrolimus will be 
administered on days –1 through 60, and then tapered. This regimen is depicted in Figure 2.  
 
The recipients will have a tunneled central line placed on Day -2 for study medication infusion and blood 
drawing. This will be removed post-transplant prior to discharge from the hospital.  
 
Prophylaxis will be provided for PCP, CMV, and perioperative infection. All participants who require a 
blood transfusion will receive only leukocyte-depleted and irradiated blood products for a period of at 
least 52 weeks following transplant. 
 
 33 


 
 
4.2 
DONOR BONE MARROW HARVEST AND NEPHRECTOMY 
 
The donor will undergo nephrectomy and bone marrow aspiration under general anesthesia. Sufficient 
marrow will be obtained to provide at least 2 × 108 nucleated cells per kilogram weight of the recipient. 
 
 
4.3 
LEUKAPHERESIS 
 
Leukapheresis will be performed x1 on the recipient prior to initiating the conditioning regimen.  
 
 
4.4 
CONDITIONING REGIMEN 
 
4.4.1 
Rituximab  (Days  –7,  –2,  5,  and  12)  
 
Rituximab will be administered in a closely monitored setting by experienced staff knowledgeable about 
infusion reactions and their effective and timely management. There should be ready access to 
equipment and medications appropriate for management of infusion reactions. In particular, 
medications and fluids for the rapid management of such reactions, including intravenous fluids, 
epinephrine, antihistamines, inhaled bronchodilators, and corticosteroids, should be readily available.55 
 
4.4.1.1  Pretreatment 
 
Acetaminophen 650 mg PO × 1, along with diphenhydramine 50 mg PO, and hydrocortisone 100 mg IV × 
1 will be given 30 minutes prior to each dose of rituximab on days −7, 5, and 12. These premedications 
will not be given before the dose of rituximab on day −2, as the subject will be premedicated before the 
first dose of MEDI-507 on day −2.  
 
4.4.1.2   Administration and Dosing  
 
Rituximab will be supplied by the local investigational pharmacy. Instructions for preparation and 
administration can be found in the package insert at: 
http://www.gene.com/gene/products/information/pdf/rituxan-prescribing.pdf 
 
Rituximab (375 mg/m2/dose) will be administered on days –7, –2, 5, and 12. Doses on days −7 and −2 
will be administered several hours after hemodialysis if hemodialysis is required. Start, stop times and 
dosage for administration will be recorded.  
 
The first rituximab solution for infusion will be administered intravenously at an initial rate of 50 
mg/hour. Escalate the rate by 50 mg/hour every 30 minutes to a maximum of 400 mg/hour. 
 
If hypersensitivity or an infusion-related event develops, the infusion should be temporarily slowed or 
interrupted. The infusion can continue at one-half the previous rate upon improvement of the subject’s 
symptoms. 
 
The second dose of rituximab will be administered on day −2, after 2–3 hours of completing the first 
dose of MEDI-507 on day –2. If the first infusion was slowed or interrupted, the initial guidelines should 
 34 


 
again be followed. Otherwise, the second infusion may be started at 100 mg/hour and titrated by 100 
mg/hour every 30 minutes to a maximum of 400 mg/hour. 
 
The third and fourth doses of rituximab will be administered in the same manner as the second dose. 
 
4.4.2 
Low dose Total Body Irradiation  (Days  –5  and  –4)  
 
4.4.2.1  Pretreatment 
Participants will be treated with anti-emetics as per institutional standard. 
 
4.4.2.2   Administration   
Total Body Irradiation of 150 cGy will be administered on Day -5 and Day -4 for a total dose of 300cGy. 
Radiation sources and dose rates will be per institutional standards 
 
4.4.3  MEDI-507 
 
4.4.3.1  Pretreatment 
 
Steroid premedication with intravenous methylprednisolone sodium succinate, 8 mg/kg up to a 
maximum dose of 500 mg, along with diphenhydramine 50 mg PO, and acetaminophen 650 mg PO will 
be administered prior to the first dose of MEDI-507 on day –2 for prophylaxis of possible first dose 
reactions. 
 
Diphenhydramine and acetaminophen may be administered at the discretion of the investigator 2 hours 
prior to the second and subsequent infusions of MEDI-507 on days –1, 0, 1, but steroid premedication 
will not be given. 
 
4.4.3.2   Administration and Dosing  
 
MEDI-507 is supplied as a clear colorless solution and does not contain a preservative. MEDI-507 bulk 
biological substance was produced by MedImmune, Inc and validated by TGA Sciences Inc. The bulk 
solution was sterilized by filtration and aseptically filled into prewashed, presterilized, depyrogenized 
vials. MEDI-507 is supplied at a concentration of  3.75 mg/mL in 4 mL vials that each contain 15 mg of 
MEDI-507. Sterile 0.9% normal saline for injection is used as diluent and supplied by MGH. The 
instructions for dose preparation and administration are given in Appendix 5. 
 
MEDI-507 should be administered at approximately the same time each day, so that there are 24 hours 
between doses.  MEDI-507 will be administered several hours after dialysis. The actual start and stop 
times of infusion will be recorded on the appropriate case report forms. If hypersensitivity or an 
infusion- related event develops, the infusion should be temporarily slowed or interrupted. The infusion 
can continue at one-half the previous rate upon improvement of subject symptoms. 
 
The first dose of MEDI-507 (day –2) will be 0.1 mg/kg, administered over 30 minutes using an infusion 
pump. The prepared 0.1-mg/kg dose will be supplied by the pharmacy to the investigator, who will 
administer the drug. The solution should be prepared to a final concentration of 0.1–0.3 mg/mL (30–100 
mL). 
 
 35 


 
The second and subsequent doses of MEDI-507 (days –1, 0, and 1) will be 0.6 mg/kg, administered over 
1 hour using an infusion pump. The day 0 infusion can be completed before or after transplant as long as 
it is consistent with the timing of the last dose. The prepared 0.6-mg/kg dose will be supplied by the 
pharmacy to the investigator, who will administer the drug. For the second and subsequent doses, a 
concentration of 0.3–1.8 mg/mL (50- to100-mL infusion volume) is permitted. 
 
The infusion may be administered using a peripheral vein, or a central line, if the latter is in place. Since 
the compatibility with other intravenously administered medications is not known, the MEDI-507 
solutions should not be infused through a common intravenous line used for other 
medications, unless the line is flushed prior to and after administration of MEDI-507. Precautions for 
“first-dose reactions” must be observed for the first and second doses of MEDI-507 (see section 4.4.3.3). 
 
4.4.3.3 Management of Reactions to Rituximab and MEDI-507  
 
“First-dose reactions” may occur upon the initial administration of rituximab or MEDI-507. These have 
the potential to be severe. Prophylaxis against first-dose reactions is described above in sections 5.4.1. 
and 5.4.3. In addition, the following procedures will be followed in assessing the occurrence of such 
reactions, and to manage adequately any acute toxic manifestations. 
 
Qualified personnel will observe each participant for a period of 2 hours after the administration of each 
of the first 2 doses of MEDI-507. Vital signs will be collected at the end of each MEDI-507 infusion. A 
physician who is a member of the transplant team and who is familiar with this protocol must be 
available and in the facility throughout this time period. Additionally, a person who is expert in 
intubation must be on call, in the facility, and available for 2 hours after the first and second doses of 
rituximab and MEDI-507 in each subject. An emergency cart must be available. Participants must remain 
under observation for at least 2 hours after completion of the infusion of the first two doses of antibody. 
 
Although acetaminophen and diphenhydramine are given prophylactically prior to administration of 
rituximab and MEDI-507, further doses of acetaminophen (650 mg PO or PR) and diphenhydramine (50 
mg PO or IV) may be administered if fever or chills occur post study drug administration. Temperature 
and other physical symptoms of the subject must be documented prior to administration of either 
medication. Corticosteroids (methylprednisolone, 250 mg IV) may be administered if a severe reaction 
occurs. All symptoms of drug reactions and treatment for drug reactions must be recorded on the 
appropriate case report forms. 
 
4.4.4 
Thymic  Irradiation  (Day –1)  
 
The 700 cGy of thymic irradiation are administered in a single dose on day –1. A field size of 
approximately 8 cm wide and 10 cm in longitudinal dimension will be used, with the midpoint of the 
upper edge of the field at the sternal notch. The dose will be calculated at a depth of approximately 6 
cm, guided by results of a lateral chest roentgenogram for the approximate location of the thymus. A 
10-MV machine at maximum dose rate should be used. No premedication for nausea should be 
required. The details regarding the field sizes, dose calculation, energy, beam spoiling, and dose rate will 
be recorded on the case report form. 
 
 
4.4.5 
Tacrolimus  Administration  and  Dosing  (Day –1)  
 
 36 


 
Tacrolimus will be administered starting on day –1. The dose will be 0.05 mg/kg twice a day, and will be 
adjusted to provide a trough whole blood concentration of 8-12 ng/mL. Substitution of generic forms of 
tacrolimus is not permitted. Tacrolimus will be continued at this level, then tapered as described in 
section 5.4.8. 
 
4.4.6 
Prednisone (Days  4–20,  22–42)  and  Methylprednisolone  (Days 22–42)  
 
To further mitigate possible symptoms of engraftment syndrome, prednisone will be started at 2 
mg/kg/day on day 4 and then tapered off by day 20.  
 
Additional corticosteroids will be administered from days 22 to 42 if the participant meets any of the 
following criteria: 
 
1.   There has been no multilineage chimerism at any time post transplant. 
 
2.   There are clinical findings suggestive of rejection and there is biopsy confirmation 
of renal allograft rejection of Banff grade IA or greater. 
 
4.4.7 
ATG Administration in the event of Engraftment Syndrome  
 
During the second post-operative week, if the creatinine begins to increase or the donor chimerism 
begins to precipitously fall (>50%), Tacrolimus will be discontinued and ATG will be given. The recipients 
can received up to 5 doses over a 10 day period during this time. Tacrolimus administration will be 
resumed after ATG is discontinued. Tacrolimus will subsequently be withdrawn as detailed in section 
4.4.8. 
 
4.4.7.1 Preparation and Storage  
For information on the preparation, storage and handling of Thymoglobulin®, please refer to the 
package insert for Thymoglobulin® (antithymocyte globulin [rabbit]) at the following website: 
http://www.thymoglobulin.com/home/thymo_pdf_pi.pdf 
 
For information on the preparation, storage and handling of ATGAM, please refer to the package insert 
for Atgam® (lymphocyte immune globulin, anti-thymocyte globulin [equine]) at the following website: 
http://www.fda.gov/downloads/biologicsbloodvaccines/bloodbloodproducts/approvedproducts/license
dproductsblas/fractionatedplasmaproducts/ucm199603.pdf  
 
4.4.7.2 Pretreatment  
Before each dose of ATG, participants will be pre-medicated with: 
• 
Methylprednisolone 100mg IV In addition participants will be pre-medicated with 
• 
Acetaminophen 650 mg PO and  
• 
Diphenhydramine 25 to 50 mg PO  
 
4.4.7.3 Administration and Dosage  
Participants may receive up to 5 intravenous doses of Thymoglobulin 1.5 mg/kg/dose or ATGAM 
15mg/kg/dose during a 10 day time period. This should be given on a QOD schedule. 
 
The first dose of ATG should be infused over a minimum of 6 hours into a high-flow vein. The vein may 
be peripheral or central per investigator discretion. Subsequent doses should be infused over at least 4 
 37 


 
hours. ATG must be given under the supervision of appropriately trained medical personnel. At any sign 
of any infusion related side effects, the infusion rate should be slowed by 50%. In the rare instance that 
anaphylaxis is reported with ATG use, the infusion should be terminated immediately and medical 
personnel should be available to treat patients who experience anaphylaxis  
 
4.4.8 
Immunosuppression Withdrawal  
 
4.4.8.1   Eligibility Criteria for  Immunosuppression  Withdrawal  
 
Tacrolimus will be tapered beginning 60 days post transplant if all of the following conditions are met: 
 
1.   There has been stable renal function (Cr < 2.0 mg/dL) for > 30 days, unless a 
transient rise in creatinine has been demonstrated to be clearly related to a known 
cause of renal dysfunction such as tacrolimus toxicity, a urologic complication, other 
drug toxicity, etc. 
 
2.   There has been no evidence of Banff grade IA or greater rejection on a renal biopsy 
obtained within the past 4 weeks.  
 
3.   There has been detectable multilineage white blood cell chimerism at any level. For 
this purpose, chimerism will be assessed by flow cytometry. 
 
4.   There has been no evidence of GVHD. 
 
5.   There is no detectable antidonor HLA antibody. 
 
Participants who do not meet these criteria the first time they are assessed will be reevaluated for 
withdrawal eligibility every 4 weeks. 
 
Participants who do not meet withdrawal criteria by 78 weeks post transplant, however, will be 
considered ineligible for and to have failed immunosuppression withdrawal, and will begin safety follow-
up as described in Section 3.4.2. 
 
4.4.8.2   Pace and Time of Completion of Immunosuppression Withdrawal  
 
Participants will withdraw from tacrolimus over no less than 12 weeks. 
 
All withdrawal attempts will be completed no later than 104 weeks post transplant. Participants who do 
not complete withdrawal by this time will be considered to have failed immunosuppression withdrawal, 
and will begin safety follow-up as described in Section 3.4.2.. 
 
4.4.8.3   Follow-up During and After Immunosuppression Withdrawal  
 
 
Participants will be followed intensively for evidence of allograft rejection during and after the 
completion of withdrawal. A chemistry panel including serum creatinine will be measured: 
• 
Weekly during withdrawal and for 3 months after tacrolimus is discontinued  
• 
Every 2 weeks for 26 weeks  
• 
Monthly for 52 weeks 
 38 


 
 
4.4.8.4   Immunosuppression Withdrawal after Episodes of Rejection  
 
Participants who experience rejection prior to completion of immunosuppression withdrawal will be 
permitted to resume immunosuppression withdrawal only if they fulfill the following criteria: 
 
1.   Stability on maintenance calcineurin inhibitor monotherapy for at least 60 days. 
 
2.   A renal biopsy that demonstrates the absence of rejection, defined as less than Banff grade IA. 
 
 
4.4.8.5   Follow-up and Treatment for Participants who Fail Immunosuppression Withdrawal  
 
Participants who have failed immunosuppression withdrawal will begin safety follow-up as detailed in 
3.4.2.2. 
 
Participants in safety follow-up will have the option of scheduling a telephone visit in lieu of a clinic visit 
every other visit when the visits are 13 weeks apart. 
 
Participants who fail immunosuppression withdrawal will be treated according to institutional standard 
at the discretion of the investigator. 
 
Participants who experience rejection following completion of immunosuppression withdrawal will be 
permitted to restart immunosuppressive therapy and attempt withdrawal at a slower pace. If such 
participants experience a second episode of rejection at any time during the second attempt, they will 
not be allowed to undergo further immunosuppression withdrawal. They will be considered to have 
failed immunosuppression withdrawal and will begin safety follow-up as described in Appendix 7. 
 
 
4.5 
TRANSPLANT PROCEDURES  
 
4.5.1 
Bone Marrow Transplant (Day 0)  
 
4.5.1.1  Preparation and Characterization of Bone Marrow Product 
 
Donor bone marrow (>1.5 × 108 nucleated cells /kg of recipient body weight) is prepared for infusion 
and characterized as outlined below. In the situation of minor ABO incompatibility, plasma will first be 
removed following centrifugation of the product. The bone marrow sample will be characterized as to 
the total volume, total nucleated cell content, total CD3+ T-cell content, and total CD34+ cell content. 
 
4.5.1.2  Infusion Procedures 
 
Allogeneic bone marrow will be rapidly infused intravenously without a filter as soon as possible 
after harvest. A total of 15,000 units of heparin is mixed with the marrow, which is infused at a rate of 
300-500 mL/hour. The infusion begins in the operating room as soon as the vascular anastomosis of the 
renal allograft has been completed. 
 
 39 


 
Protamine, 25 mg, is administered IV after completion of the first half of the bone marrow infusion. If a 
partial thromboplastin time measured after completion of the marrow infusion is greater than 
60 seconds, the Protamine treatment will be repeated. 
 
4.5.2 
Renal Transplant (Day 0)  
 
Prophylactic antimicrobial therapy will be administered prior to surgery according to institutional 
practice. 
 
4.5.2.1  Surgical Procedure 
 
The renal transplant is performed according to standard surgical techniques. A ureteral stent should be 
placed if surgically feasible. 
 
4.5.2.2   Intra-operative  Renal  Biopsy  
 
A wedge biopsy will be obtained on the day of transplant and sent for routine pathology diagnostics 
(please refer to section 5.4.2). 
 
4.6 
PROPHYLAXIS AGAINST AND TREATMENT OF INFECTION  
 
4.6.1 
Pneumocystis and Urinary Tract Infections  
 
Trimethoprim and Sulfamethoxazole (TMP/SMX), one single- or double-strength tablet daily will be 
administered to all participants starting at the initiation of the conditioning regimen (day −7) and 
continuing until the day of transplantation. It will be restarted the day neutrophil counts exceed 
500/µL and continued until 24 weeks post transplant. 
 
In the event of allergy or intolerance to the components of TMP/SMX, atovoquone, 1.5 g PO each day 
will be used in its place for prophylaxis of Pneumocystis carinii. 
 
Consideration will be given to extending the period of prophylaxis for an additional 6 months if it is felt 
to be clinically indicated, since TMP/SMX provides prophylaxis against the majority of isolates of 
pneumococcus and H. influenza. 
 
Levofloxacin, 250–500 mg daily (as a suitable quinolone substitute), will be started at the onset of 
neutropenia (ANC <0.5) and continued until resolution of the neutropenia (ANC >0.5). 
 
4.6.2 
Fungal and Yeast Infections  
 
Post-transplant prophylaxis for fungal infections will be administered at the discretion of the 
investigator. 
 
4.6.3 
CMV Infection  
 
4.6.3.1   Prophylaxis  When  at  Least  One  of  the  Donor–Recipient  Pair  is  Seropositive  
 
 40 


 
Cytomegalovirus prophylaxis is central to the successful outcome of BMT and organ transplantation. All 
BMT participants should receive seronegative or CMV “safe” blood (leukofiltered). The greatest risk for 
CMV infection in solid organ transplantation is for the donor seropositive (D+) into recipient 
seronegative (R−) combination. In hematopoietic stem-cell transplantation, CMV pneumonitis is most 
common in the D− into R+ combination. Given that CMV infection may occur in any combination in 
which at least one of the donor–recipient pair is seropositive, a uniform approach for such cases is most 
reasonable in terms of preventing invasive infection. To this end, each recipient under this protocol will: 
 
1.   Have the serologic status obtained for donor and recipient. 
 
2.   Be monitored weekly by quantitative CMV DNA PCR assay while neutropenic and following 
engraftment. 
 
3.   Receive Ganciclovir 5 mg/kg × 1 dose prior to renal transplantation (day −1). 
 
4.   Subsequently receive CMV prophylaxis per institutional standards after the ANC exceeds 
1000.  
 
4.6.3.2   Prophylaxis in Individuals when Donors-Recipients are both Seronegative  
 
Provided CMV-negative pedigreed blood products are utilized, there is a very low risk of CMV disease 
when both donor and recipient are seronegative. Therefore, in such cases, CMV prophylaxis will not be 
given. To prevent the 40% incidence of herpes simplex disease that occurs in transplant patients not 
receiving ganciclovir, oral acyclovir 400 mg TID or other approved antiviral therapy will be prescribed for 
4–6 months. 
 
4.6.3.3   Treatment of CMV Infection 
 
Initial treatment of CMV disease (defined by CMV PCR) is for a minimum of 2–3 weeks with intravenous 
ganciclovir at a dose of 5 mg/kg twice daily (with dosage adjustment for renal dysfunction), oral 
valganciclovir 900 mg PO BID, or other approved antiviral medication per institutional standards. CMV 
IgG (150 mg/kg q 4 weeks) will be added for seronegative participants 
at the discretion of the investigator. The endpoint of intravenous therapy is the documented clearance 
of virus from the blood as demonstrated by CMV antigenemia assay or quantitative PCR assay. 
 
The risk of subsequent relapse is ~15%–20%, so treatment will be continued for at least 3 months. With 
3 months of oral therapy following clearance of viremia, the rate of relapse is decreased substantially. 
 
In participants with relapsing infection, initial treatment is repeated. CMV hyperimmune globulin (at a 
dose of 150 mg/kg IV once and 100 mg/kg IV q month × 3–6) is usually administered in conjunction with 
the intravenous ganciclovir, oral valganciclovir or other approved therapy for seronegative recipients at 
the discretion of the investigator. Treatment will be maintained in the setting of active GVHD. 
 
Table 2. Dosing nomogram for treatment of CMV infection 
 
Serum Creatinine 
(mg/dL) 
Intravenous Dose 
(mg/kg) 
Frequency 
<2.0 
5 
Q12h 
 41 


 
2–3 
5 
Daily 
3–5 
1.25 
Daily 
>5.0 
1.25* 
QOD 
Hemodialysis 
5 
Post dialysis 
Peritoneal dialysis 
2.5* 
Daily 
 
 
*After a loading dose of 5 mg/kg. All patients (prophylaxis or therapeutic) receive leukocyte or CMV-
negative blood; CMV-hyperimmune globulin (Massachusetts Red Cross) 150 mg/kg IV for the first dose 
and 100mg/kg × 4 at the discretion of the physician. 
 
4.6.4 
Herpes  Infection  
 
CMV prophylaxis as described in section 4.6.3 will also serve as prophylaxis against herpes infection. 
 
4.7 
ASSESSMENT OF ALLOGRAFT DYSFUNCTION AND TREATMENT OF RENAL REJECTION 
 
4.7.1 
Definition of Allograft Dysfunction and Indication for Biopsy  
 
Renal allograft dysfunction is defined as an increase in creatinine of 25% or greater compared to the 
baseline creatinine post transplant. Baseline is defined as an average of the 3 lowest creatinines during 
weeks 2-4 post transplant, excluding days on dialysis.  
 
If allograft dysfunction is unexplained and persists for greater than 72 hours, a renal biopsy must be 
performed to rule out acute rejection. If the biopsy does not demonstrate rejection, further evaluation 
for other causes of renal dysfunction will be performed. 
 
4.7.2 
Diagnosis, Grading and Monitoring of Rejection  
 
Renal allograft biopsies will be used to diagnose and grade rejection. Biopsies will be assigned a Banff 
grade according to the most current Banff Classification of Renal Allograft Pathology.  
 
4.7.2.1 Humoral (Antibody-mediated) Rejection 
 
Humoral rejection is defined according to the Banff Classification of Renal Allograft Pathology (see 
Appendix 2). 
 
4.7.2.2   Acute Cellular Rejection  
 
A Banff score of grade IA or above will constitute acute cellular rejection (see Appendix 2). 
 
4.7.2.3   Chronic Rejection 
 
Chronic rejection (both humoral and cellular) is defined according to the Banff Classification of 
Renal Allograft Pathology (see Appendix 2). 
 
4.7.3 
Treatment of Rejection  
 42 


 
 
If participants show evidence of graft rejection, standard rejection therapy will be initiated according to 
institutional protocol. Specific therapy for rejection may include any or all of the following: Solumedrol, 
Thymoglobulin, Campath, or other antilymphocyte antibody therapies and local irradiation of the kidney 
allograft. Plasmapheresis, IVIg, Rituximab and Velcade may be utilized if humoral rejection is diagnosed. 
A renal biopsy will be performed within 14 days of completion of treatment for rejection to document 
response to therapy. After biopsy confirmation of resolution of rejection, the participant will be weaned 
to maintenance therapy as defined by institutional practices. Maintenance therapy may include any or 
all of the following medications: tacrolimus, cyclosporine, sirolimus, steroids, azathioprine, and/or MMF. 
It is recognized that graft failure and return to dialysis may occur despite these measures, and such an 
outcome will be included in the consent forms and discussed with the participant. 
 
For participants with findings “suspicious” for acute cellular rejection (less than grade IA rejection), 
additional maintenance immunosuppressive therapy will not be instituted even if they are treated for 
rejection based on clinical need. However, these participants will be rebiopsied within 3–4 weeks, 
closely monitored for further histological or clinical evidence of rejection, and considered for 
subsequent tacrolimus taper and discontinuation. 
 
For participants who receive antilymphocyte antibody therapy, antiviral and antipneumocystosis 
prophylaxis will be administered for an additional 10 weeks at the discretion of the investigator.  
 
4.8 
PROHIBITED MEDICATIONS 
 
No concomitant immunosuppressants aside from rituximab and MEDI-507 (or others specified in this 
protocol) may be administered during the conditioning regimen. If such therapy is required, the 
conditioning regimen must be stopped, and the participant will be considered to have prematurely 
discontinued study therapy (section 4.4). The administration of any live or investigational vaccine is 
prohibited for all participants on the study from 30 days prior to transplantation (day −30) until 60 days 
following transplantation (day 60). 
 
4.9 
DRUG ACCOUNTABILITY 
 
Under Title 21 of the Code of Federal Regulations (21CFR §312.62) the investigator is required to 
maintain adequate records of the disposition of the investigational agent, including the date and 
quantity of the drug received, to whom the drug was dispensed (participant-by-participant accounting), 
and a detailed accounting of any drug accidentally or deliberately destroyed. Records for receipt, 
storage, use, and disposition will be maintained by the study site. A drug-dispensing log containing the 
patient identification number and the date and quantity of drug dispensed will be maintained for each 
participant.  
 
5. 
STUDY PROCEDURES 
 
5.1 
GENERAL ASSESSMENTS 
 
Informed consent: Written informed consent will be obtained before any study-related assessments or 
procedures are performed. 
 
• 
Physical examination 
 43 


 
o At Screening 
o At each inpatient or outpatient visit 
• 
Medical history: Medical history will include psychosocial evaluation and previous transplant 
history 
o At Screening 
• 
Cardiac function—echocardiogram. 
o At Screening 
• 
Pulmonary function—chest x-ray and PFTs (DLCO, spirometry & Lung volumes) 
o At Screening 
• 
GVHD: GVHD will be staged and graded as in Appendix 3. 
o Daily while hospitalized 
o At each outpatient visit until chimerism undetectable 
• 
Leukapheresis 
o Prior to Day -7 
• 
Protocol Renal biopsy 
o Day 10 
o Month 6 
o Month 9 
o Year 1 
o Year 2 
o Year 3 
 
 
5.2 
LABORATORY ASSESSMENTS 
 
• 
Hematology—CBC with differential and platelets 
o At Screening 
o Daily while hospitalized 
o At each outpatient visit 
• 
Serum chemistry—ALT, AST, BUN, AP, bilirubin, albumin, total protein 
o At Screening 
o Weekly while hospitalized 
o At each outpatient visit 
• 
Basic chemistry—electrolytes, glucose, BUN, and creatinine 
o Daily while hospitalized 
o At each outpatient visit 
o See section 4.9.3 for monitoring during and after immunosuppression withdrawal 
• 
Coagulation studies—PT/INR and PTT 
o At screening 
o Week 1 
o Day 10 (with biopsy) 
o Month 9 (with biopsy) 
o Every 6 months thereafter  
• 
Thyroid function—T3, FT4, and TSH 
o At Screening 
o Every 6 months thereafter 
• 
Serum pregnancy test 
 44 


 
o At Screening 
• 
HLA typing – by intermediate resolution for HLA-A, B, C, DRB1, DQA1 and DQB1  
o At Screening 
• 
ABO typing 
o At Screening 
• 
T and B Cell  crossmatch by Flow Cytometry and Cytotoxicity 
o At Screening 
• 
HLA alloantibodies per routine methodology (AHG and/or ELISA)  
o At Screening 
o Prior to Initiation of Day -7 Treatment 
o Weekly - Weeks 1-6 
o Every other month for 3 years 
o Year 4  
o Year 5 
• 
Viral and syphilis serology–CMV IgG, HIV I/II, HbsAg, HbsAb, HCV, EBV, and syphilis 
o At Screening 
• 
Tacrolimus levels 
o Daily Post-Transplant while hospitalized 
o At each outpatient visit  
o May discontinue when level is undetectable after immunosuppression withdrawal 
• 
BK virus PCR (blood) 
o Week 1 
o Every other month thereafter  
• 
Chimersim 
o 2x/ Week starting on Day 7 until chimerism is undetectable 
• 
Research Testing 
This is a 2 patient pilot trial, no funding is provided for in vitro research studies. A minimal volume of 
blood (< 40 cc / week) will be drawn and stored for potential future research studies. If the 
leukapheresis that is collected pre-transplant is not used to treat GVHD, this will be used for 
potential future research studies as well.  
 
 
5.3 
RENAL BIOPSY 
 
5.3.1. RENAL CORE BIOPSIES 
 
Participants will undergo surveillance renal core biopsies Day 10-12, 6 months, 1 Year, 2 Years and 3 
Years post transplant. These biopsies will be used to monitor function and to screen for subclinical 
rejection. 
 
5.3.2  INTRA-OPERATIVE WEDGE BIOPSY  
 
A 3 × 5-mm wedge biopsy will be obtained on the day of transplant to assess for any evidence of donor 
disease.  
 
5.3.3   For-cause Biopsies  
 
 45 


 
For-cause biopsies will be obtained to confirm suspected rejection following unexplained allograft 
dysfunction. 
 
6. 
ADVERSE EVENTS 
 
6.1 
OVERVIEW 
 
This section defines the types of adverse events and outlines the procedures for appropriately 
collecting, grading, recording, and reporting them. Information in this section complies with ICH 
Guideline E2A: Clinical Safety Data Management: Definitions and Standards for Expedited Reporting, ICH 
Guideline E-6: Guideline for Good Clinical Practice, and applies the standards set forth in the National 
Cancer Institute (NCI), Common Terminology Criteria for Adverse Events, Version 4.0 (May 28, 2009). 
 
6.2 
DEFINITIONS 
 
6.2.1 
Adverse Event  
 
An adverse event is any occurrence or worsening of an undesirable or unintended sign, symptom, 
laboratory finding, or disease that occurs during participation in the trial. 
 
An adverse event will be followed until it resolves or until 30 days after a participant terminates from 
the study, whichever comes first. 
 
6.2.2 
Serious Adverse Event  
 
An SAE or reaction is defined as any adverse event that suggests a significant hazard, contraindication, 
side effect, or precaution. This includes but is not limited to any of the following events: 
 
• 
Death: A death that occurs during the study or that comes to the attention of the investigator 
during the protocol-defined follow-up after the completion of therapy must be reported 
whether it is considered treatment related or not. 
 
• 
A life-threatening event: A life-threatening event is any adverse therapy experience that, in the 
view of the investigator, places the participant at immediate risk of death from the reaction as it 
occurred. 
 
• 
Inpatient hospitalization or prolongation of existing hospitalization. 
 
• 
Persistent or significant disability. 
 
• 
An event that requires intervention to prevent permanent impairment or damage. An important 
medical event that may not result in death, be life threatening, or require hospitalization may be 
considered an SAE when, based on appropriate medical judgment, it may jeopardize the 
participant and may require medical or surgical intervention to prevent one of the outcomes 
listed above. 
 
• 
Congenital anomaly or birth defect. 
 46 


 
 
Regardless of the relation of the adverse event to study participation, the event must be reported as a 
serious adverse event if it meets any of the above definitions. 
 
6.2.3 
Unexpected Adverse Event  
 
An adverse event is considered “unexpected” when its nature or severity is not consistent with 
applicable product information described in the safety information provided in the investigator’s 
brochure for MEDI-507 or package inserts for study medications in section 4. The package inserts that 
apply are those for Rituxan (rituximab),Thymoglobulin, ATGAM, prednisone, Prograf (tacrolimus).  
 
6.3 
COLLECTING ADVERSE EVENTS 
 
Adverse events will be collected from the time the participant is enrolled until 30 days after the 
participant completes the study. Prior to the beginning of study treatment, only adverse events related 
to screening assessments will be reported. 
 
Adverse events may be discovered through any of these methods: 
 
• 
Observing the participant. 
 
• 
Questioning the participant in an objective manner. 
 
• 
Receiving an unsolicited complaint from the participant. 
 
An abnormal value or result from a clinical or laboratory evaluation (e.g., a radiograph, an ultrasound, or 
an electrocardiogram) can also indicate an adverse event. If this is the case, then the evaluation 
that produced the value or result should be repeated until that value or result returns to normal or can 
be explained and the participant’s safety is not at risk. If an abnormal value or result is determined by 
the investigator to be clinically significant, it must be recorded as an adverse event on the appropriate 
case report form(s). 
 
The investigator will treat participants experiencing adverse events appropriately and observe them at 
suitable intervals until their symptoms resolve or their status stabilizes. 
 
 
6.4 
GRADING, ATTRIBUTION AND REPORTING OF ADVERSE EVENTS 
 
6.4.1 
Grading  Criteria  
 
The study site will grade the severity of adverse events experienced by ITN study participants according 
to the criteria set forth in the National Cancer Institute’s Common Toxicity Criteria for Adverse Events 
Version 4.0 (published May 28, 2009). This document (referred to herein as the NCI-CTCAE manual) 
provides a common language to describe levels of severity, to analyze and interpret data, and to 
articulate the clinical significance of all adverse events. For additional information and a printable 
version of the NCI-CTCAE manual, consult the NCI-CTCAE web site: 
http://ctep.cancer.gov/reporting/ctc.html. 
 
 47 


 
Adverse events will be graded on a scale from 1 to 5 according to the following standards in the NCI- 
CTCAE manual: 
 
Grade 1 = mild adverse event. 
 
Grade 2 = moderate adverse event. 
 
Grade 3 = severe and undesirable adverse event. 
 
Grade 4 = life-threatening or disabling adverse event. 
 
Grade 5 = death. 
 
6.4.2 
Attribution  Definitions  
 
Adverse events will be categorized for their relation to each of the following: 
 
• 
MEDI-507 
• 
Total Body Irradiation 
• 
Rituximab 
• 
Tacrolimus (or other CNI) 
• 
Other study medications and procedures 
 
The relation, or attribution, of an adverse event to MEDI-507 and other study medications and 
procedures will be determined by the site investigator. The investigator will also record the 
determination of attribution on the appropriate CRF and/or SAE reporting form. The relation of an 
adverse event to MEDI-507 or other study medications and procedures will be determined using the 
descriptors and definitions provided in Table 6. 
 
Table 3. Attribution of adverse events 
 
Code 
Descriptor 
Definition 
Unrelated Category 
1 
Unrelated 
The adverse event is clearly not related. 
Related Categories 
2 
Unlikely 
The adverse event is doubtfully related. 
3 
Possible 
The adverse event may be related. 
4 
Probable 
The adverse event is likely related. 
5 
Definite 
The adverse event is clearly related. 
 
 
6.4.3.   Adverse Event Reporting Requirements  
 
Adverse events that are < Grade 2 will not be reported.  
 
 
7. 
STATISTICAL CONSIDERATIONS AND ANALYTICAL PLAN 
 48 


 
 
7.1 
ANALYSIS SAMPLES 
 
Given a sample size of 2 participants, the analyses will be descriptive. However, to the extent possible, 
estimates obtained in the study will be interpreted in the context of the data from historical cohorts.  
 
8. 
QUALITY CONTROL AND QUALITY ASSURANCE 
 
The investigator is required to keep accurate records to ensure that the conduct of the study is fully 
documented.  
 
 
9. 
ETHICAL CONSIDERATIONS AND COMPLIANCE WITH GOOD CLINICAL PRACTICE 
 
 
9.1 
STATEMENT OF COMPLIANCE 
 
This trial will be conducted in compliance with the protocol, with current good clinical practices 
(GCP), the principles of the Declaration of Helsinki, and with all applicable regulatory requirements. 
 
Before study initiation, the protocol and the informed consent documents will be reviewed and 
approved by an appropriate ethics review committee or institutional review board. Any amendments to 
the protocol or to the consent materials must also be approved before they are implemented. 
 
 
9.2 
INFORMED CONSENT 
 
The informed consent form is a means of providing information about the trial to a prospective 
subject and allows for an informed decision about participation in the study. All participants (or their 
legally acceptable representative) must read, sign, and date a consent form before entering the study, 
taking study drug, or undergoing any study-specific procedures. Consent materials for participants who 
do not speak or read English must be translated into the participants’ appropriate language. 
 
The informed consent form must be revised whenever important new safety information is available, 
whenever the protocol is amended, and/or whenever any new information becomes available that may 
affect participation in the trial. 
 
A copy of the informed consent will be given to a prospective participant for review. The attending 
physician, in the presence of a witness, will review the consent and answer questions. The prospective 
participant will be told that being in the trial is voluntary and that he/she may withdraw from the study 
at any time, for any reason. 
 
 
9.3 
PRIVACY AND CONFIDENTIALITY 
 
A participant’s privacy and confidentiality will be respected throughout the study. Each participant will 
be assigned a sequential identification number, and these numbers rather than names will be used to 
collect, store, and report participant information. 
 49 


 
 
 
 
References 
 
1. Murray JE, Merrill JP, Harrison JH. Kidney transplantation between seven pairs of identical twins. Ann 
Surg 1958;148(3):343-59. 
2. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United 
States: the long-term does not mirror the dramatic short-term success. Am J Transplant;11(6):1226-35. 
3. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival 
despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 
2004;4(3):378-83. 
4. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney 
transplantation. J Am Soc Nephrol 2005;16(2):496-506. 
5. Miller LW. Cardiovascular toxicities of immunosuppressive agents. Am J Transplant 2002;2(9):807-18. 
6. Morales JM, Dominguez-Gil B. Cardiovascular risk profile with the new immunosuppressive 
combinations after renal transplantation. J Hypertens 2005;23(9):1609-16. 
7. Dharnidharka VR, Caillard S, Agodoa LY, Abbott KC. Infection frequency and profile in different age 
groups of kidney transplant recipients. Transplantation 2006;81(12):1662-7. 
8. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: 
current epidemiology and associated risk factors. Clin Transplant 2006;20(4):401-9. 
9. Snyder JJ, Israni AK, Peng Y, Zhang L, Simon TA, Kasiske BL. Rates of first infection following kidney 
transplant in the United States. Kidney Int 2009;75(3):317-26. 
10. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and 
incidence of cardiovascular disease, malignancy and infection. Drugs 2009;69(16):2227-43. 
11. Rama I, Grinyo JM. Malignancy after renal transplantation: the role of immunosuppression. Nat Rev 
Nephrol;6(9):511-9. 
12. Adami J, Gabel H, Lindelof B, et al. Cancer risk following organ transplantation: a nationwide cohort 
study in Sweden. Br J Cancer 2003;89(7):1221-7. 
13. London NJ, Farmery SM, Will EJ, Davison AM, Lodge JP. Risk of neoplasia in renal transplant patients. 
Lancet 1995;346(8972):403-6. 
14. Scantlebury V, Shapiro R, Fung J, et al. New onset of diabetes in FK 506 vs cyclosporine-treated 
kidney transplant recipients. Transplant Proc 1991;23(6):3169-70. 
15. Jindal RM, Sidner RA, Milgrom ML. Post-transplant diabetes mellitus. The role of 
immunosuppression. Drug Saf 1997;16(4):242-57. 
16. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 
2000;23(7):482-90. 
17. Jevnikar AM, Petric R, Holub BJ, Philbrick DJ, Clark WF. Effect of cyclosporine on plasma lipids and 
modification with dietary fish oil. Transplantation 1988;46(5):722-5. 
18. Nemunaitis J, Deeg HJ, Yee GC. High cyclosporin levels after bone marrow transplantation associated 
with hypertriglyceridaemia. Lancet 1986;2(8509):744-5. 
19. Abouljoud MS, Levy MF, Klintmalm GB. Hyperlipidemia after liver transplantation: long-term results 
of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group. Transplant Proc 
1995;27(1):1121-3. 
20. McCune TR, Thacker LR, II, Peters TG, et al. Effects of tacrolimus on hyperlipidemia after successful 
renal transplantation: a Southeastern Organ Procurement Foundation multicenter clinical study. 
Transplantation 1998;65(1):87-92. 
 50 


 
21. Ponticelli C, Campise MR. Neurological complications in kidney transplant recipients. J Nephrol 
2005;18(5):521-8. 
22. Wijdicks EF. Neurotoxicity of immunosuppressive drugs. Liver Transpl 2001;7(11):937-42. 
23. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United 
States. Am J Transplant 2004;4(6):905-13. 
24. Wimmer CD, Rentsch M, Crispin A, et al. The janus face of immunosuppression - de novo malignancy 
after renal transplantation: the experience of the Transplantation Center Munich. Kidney Int 
2007;71(12):1271-8. 
25. Briganti EM, Russ GR, McNeil JJ, Atkins RC, Chadban SJ. Risk of renal allograft loss from recurrent 
glomerulonephritis. N Engl J Med 2002;347(2):103-9. 
26. Lonze BE, Warren DS, Stewart ZA, et al. Kidney transplantation in previous heart or lung recipients. 
Am J Transplant 2009;9(3):578-85. 
27. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA antibodies: a prospective trial. Am J 
Transplant 2004;4(3):438-43. 
28. Lodhi SA, Meier-Kriesche HU. Kidney allograft survival: the long and short of it. Nephrol Dial 
Transplant;26(1):15-7. 
29. Pascual M, Theruvath T, Kawai T, Tolkoff-Rubin N, Cosimi AB. Strategies to improve long-term 
outcomes after renal transplantation. N Engl J Med 2002;346(8):580-90. 
30. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant 
recipients. Transplantation 1997;63(2):243-9. 
31. Koshiba T, Li Y, Takemura M, et al. Clinical, immunological, and pathological aspects of operational 
tolerance after pediatric living-donor liver transplantation. Transpl Immunol 2007;17(2):94-7. 
32. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by 
a nonlethal preparative regimen. J Exp Med 1989;169(2):493-502. 
33. Sykes M, Sachs DH. Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 2001;356(1409):707-26. 
34. Fuchimoto Y, Huang CA, Yamada K, et al. Mixed chimerism and tolerance without whole body 
irradiation in a large animal model. J Clin Invest 2000;105(12):1779-89. 
35. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in 
cynomolgus monkeys. Transplantation 1995;59(2):256-62. 
36. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and alloantibody production in a non-
myeloablative regimen for induction of renal allograft tolerance. Transplantation 1999;68(11):1767-75. 
37. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and 
prolonged renal allograft survival in nonhuman primates. Am J Transplant 2004;4(9):1391-8. 
38. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-
matched donor bone marrow and renal transplantation for multiple myeloma with end stage renal 
disease: the induction of allograft tolerance through mixed lymphohematopoietic chimerism. 
Transplantation 1999;68(4):480-4. 
39. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-Term Follow-Up of Recipients of Combined Human 
Leukocyte Antigen-Matched Bone Marrow and Kidney Transplantation for Multiple Myeloma With End-
Stage Renal Disease. Transplantation. 
40. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance 
immunosuppression. N Engl J Med 2008;358(4):353-61. 
41. Ildstad ST, Sachs DH. Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow 
leads to specific acceptance of allografts or xenografts. Nature 1984;307(5947):168-70. 
42. Sharabi Y, Sachs DH. Engraftment of allogeneic bone marrow following administration of anti-T cell 
monoclonal antibodies and low-dose irradiation. Transplant Proc 1989;21(1 Pt 1):233-5. 
 51 


 
43. Wekerle T, Sayegh MH, Ito H, et al. Anti-CD154 or CTLA4Ig obviates the need for thymic irradiation in 
a non-myeloablative conditioning regimen for the induction of mixed hematopoietic chimerism and 
tolerance. Transplantation 1999;68(9):1348-55. 
44. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the 
conditioning regimen for achieving mixed chimerism and donor-specific tolerance in cynomolgus 
monkeys. Transplantation 1997;64(5):709-16. 
45. Wekerle T, Sayegh MH, Hill J, et al. Extrathymic T cell deletion and allogeneic stem cell engraftment 
induced with costimulatory blockade is followed by central T cell tolerance. J Exp Med 
1998;187(12):2037-44. 
46. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and 
hematopoietic-cell transplantation. N Engl J Med 2008;358(4):362-8. 
47. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney 
transplantation. N Engl J Med 2011;365(14):1359-60. 
48. Leventhal J, Abecassis M, Miller J, et al. Chimerism and Tolerance Without GVHD or Engraftment 
Syndrome in HLA-Mismatched Combined Kidney and Hematopoietic Stem Cell Transplantation. Sci 
Transl Med 2012;4(124):124ra28. 
49. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001;14(4):417-24. 
50. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney 
and nonmyeloablative marrow transplantation: in vivo and in vitro analyses. Am J Transplant 
2006;6(9):2121-33. 
51. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence 
for early donor-specific unresponsiveness in patients receiving combined kidney and bone marrow 
transplantation to induce tolerance. Transplantation;90(12):1607-15. 
52. Farris AB, Taheri D, Kawai T, et al. Acute renal endothelial injury during marrow recovery in a cohort 
of combined kidney and bone marrow allografts. Am J Transplant 2011;11(7):1464-77. 
 
 52 


 
 
Appendix 1. Diagnosis and Classification of Selected Opportunistic Infections 
 
Cytomegalovirus Infections 
 
1.   Seroconversion: Change from CMV seronegative status to seropositive after transplantation as 
determined by an accepted serologic test, using the manufacturers criteria for seroconversion. The type 
of test used should be specified. 
 
2.   Shedding (urine, throat): A positive culture, whether conventional or by rapid antigen test 
(“shell vial”), without evidence of clinical disease. 
 
3.   Viremia or antigenemia: A positive culture from blood or buffy coat, whether by conventional 
culture, or rapid antigen test (“shell vial”), or immunochemical testing. 
 
4.   Disseminated/syndrome: A positive culture from blood or buffy coat, or another site, as above, in 
association with a compatible clinical illness consisting of fever and leukopenia, with or without liver 
function test abnormalities. 
 
5.   End organ disease (specify site): Clinical signs plus a positive culture of a normally sterile site, 
preferably the organ involved, or positive histology with appropriate clinical signs (gut, lung, retina, liver, 
etc.). Must be considered presumptive if positive clinical signs or laboratory test results are found, but 
no definitive evidence of viral invasion is present (positive culture, presence of antigen, positive 
histology). 
 
Herpes Zoster Infections 
 
1.   Localized: Dermatomal distribution of a single or 2 adjacent dermatomes with no crossing the 
midline. 
 
2.   Skin dissemination: Lesions in more than 2 dermatomes, crossing the midline, or multiple isolated 
lesions on the skin, with no evidence of internal organ involvement (e.g. brain, lungs, liver, gut, 
peritoneum). 
 
3.   Disseminated: Internal organ involvement by histology or compatible clinical syndrome with 
characteristic skin involvement. 
 
Candida Infections 
 
1.   Mucosal: Mucosal involvement (oropharynx, GU tract) without systemic signs or symptoms 
attributable to Candida. 
 
2.   Candidemia: Positive culture of blood or intravenous access device tip, with or without fever. 
 
3.   Invasive: Positive culture of a normally sterile site, or positive histologic evidence of tissue invasion 
(skin [hematogenous], gut, liver, spleen, retina, lung, kidney), including positive blood culture in absence 
of an infected intravenous device. 
 53 


 
Appendix 2. Current Banff Classification of Renal Allograft Pathology (Banff 2007)1 
 
 
1. Normal 
 
2. Antibody-mediated changes (may coincide with catagories 3, 4 and 5 and 6) 
 
Due to documentation of circulating antidonor antibody, C4d,1 and allograft 
pathology 
 
C4d deposition without morphologic evidence of active rejection 
 
C4d+, presence of circulating antidonor antibodies, no signs of acute or chronic 
TCMR or ABMR (i.e. g0, cg0, ptc0, no ptc lamination (<5 layers by electron 
microscopy), no ATN-like minimal inflammation). Cases with simultaneous 
borderline changes are considered as indeterminate 
 
 
Acute antibody-mediated rejection2 
C4d+, presence of circulating antidonor antibodies, morphologic evidence of acute tissue injury, such as 
(Type/Grade) 
Type I. ATN-like minimal inflammation 
Type II. Capillary and or glomerular inflammation (ptc/g >0) and/or thromboses 
Type III. Arterial—v3 
 
Chronic active antibody-mediated rejection2  
C4d+, presence of circulating antidonor antibodies, morphologic evidence of chronic tissue injury, such 
as glomerular double contours and/or peritubular capillary basement membrane multilayering and/or 
interstitial fibrosis/tubular atrophy and/or fibrous intimal thickening in arteries 
 
3. Borderline changes: ‘Suspicious’ for acute T-cell mediated rejection (may coincide with categories 2 
and 5, and 6) 
 
This category is used when no intimal arteritis is present, but there are foci of tubulitis (t1, t2 or t3) with 
minor interstitial infiltration (i0 or i1) or interstitial infiltration (i2, i3) with mild (t1) tubulitis 
 
4. T-cell mediated rejection (TCMR, may coincide with categories 2 and 5 and 6) 
 
Acute T-cell mediated rejection (Type/Grade:): 
 
IA. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of 
moderate tubulitis (t2) 
IB. Cases with significant interstitial infiltration (>25% of parenchyma affected, i2 or i3) and foci of 
severe tubulitis (t3)  
IIA. Cases with mild to moderate intimal arteritis (v1) 
IIB. Cases with severe intimal arteritis comprising >25% of the luminal area (v2)  
III. Cases with ‘transmural’ arteritis and/or arterial fibrinoid change and necrosis of medial smooth 
muscle cells with accompanying lymphocytic inflammation (v3) 
 54 


 
 
Chronic active T-cell mediated rejection 
‘chronic allograft arteriopathy’ (arterial intimal fibrosis with mononuclear cell infiltration in fibrosis, 
formation of neo -intima) 
 
5. Interstitial fibrosis and tubular atrophy, no evidence of any specific etiology 
 (may include nonspecific vascular and glomerular sclerosis, but severity graded by tubulointerstitial 
features) 
 
 Grade 
I. Mild interstitial fibrosis and tubular atrophy (<25% of cortical area) 
II. Moderate interstitial fibrosis and tubular atrophy (26–50% of cortical area) 
III. Severe interstitial fibrosis and tubular atrophy/ loss (>50% of cortical area) 
 
6. Other: Changes not considered to be due to rejection- acute and/or chronic (For diagnoses see table 
14 in (49); may include isolated g, cg, or cv lesions and coincide with categories 2, 3, 4, and 5) 
 
 
1Please refer to Banff 2007 classification paper http://onlinelibrary.wiley.com/doi/10.1111/j.1600-
6143.2009.02987.x/abstract 
 
2Suspicious for antibody-mediated rejection if C4d (in the presence of antibody) or alloantibody (C4d+) 
not demonstrated in the presence of morphologic evidence of tissue injury. 
 
 
B. Sis1,2,*, M. Mengel1,2, M. Haas3,R. B. Colvin4, et al., Banff ’09 Meeting Report: Antibody Mediated Graft 
Deterioration and Implementation of Banff Working Group. Am J Transplant, 2009;10:464-471  
http://onlinelibrary.wiley.com/doi/10.1111/j.1600-6143.2009.02987.x/abstract 
 55 


 
 
Appendix 3. Staging and Grading of Graft-Versus-Host Disease 
 
Organ Staging of Graft-Versus-Host Disease 
 
Stage 
Skin 
Liver 
Gut 
1 
Maculopapular rash, <25% 
of body surface a 
Bilirubin 
2–3 mg/dL b 
500–999 mL diarrhea/day c, or persistent 
nausea with histologic evidence of GVHD 
in stomach or duodenum 
2 
Maculopapular rash, 25%– 
50% of body surface a 
Bilirubin 
3.1–6 mg/dL b 
1000-1499 mL diarrhea/day c 
3 
Maculopapular rash, 
> 50% of body surface a 
Bilirubin 
6.1–15 mg/dL b 
1500 or more mL diarrhea/day c 
4 
Generalized erythroderma 
with bullous formation 
Bilirubin 
>15 mg/dl b 
Severe abdominal pain with or without 
ileus 
a Use “Rule of Nines” to determine extent of rash. 
b Range given as total bilirubin. Downgrade one stage if an additional cause of elevated bilirubin has 
been documented. 
c Downgrade one stage if an additional cause of elevated bilirubin has been documented. 
 
 
 
 
Overall Clinical Grading of Severity of Acute GVHD a 
 
Grade 
Degree of Organ Involvement 
I 
Stage 1-2 rash and no liver or gut involvement 
II 
Stage 3 rash, or stage 1 liver involvement, or stage 1 gut involvement 
III 
None to stage 3 skin rash with stage 2–3 liver, or stage 2–4 gut involvement 
IV 
Stage 4 skin rash, or stage 4 liver involvement 
a Adapted from Thomas ED, Storb R, Clift RA, et al. Bone-marrow transplantation (second of two parts). 
N Engl J Med. April 24, 1975;292(17):895-902. 
 
 
 
 
 
 
 
 56 


 
 
Appendix 4. Donor Evaluations 
 
Organ Transplantation Protocol for Donor Screening 
The initial examination of potential living donors will include: 
 
• 
Evaluation by appropriate staff psychiatrist. 
 
• 
HLA typing (by Intermediate resolution) HLA-A, B, C, DRB1, DQA1 and DQB1.. B- and T-cell 
crossmatch tests will also be performed. 
 
• 
Determination of ABO blood group. 
 
If the donor is found to be mentally suitable and compatible for blood and tissue types, the following 
will be performed: 
 
• 
Health history questionnaire 
 
• 
Physical examination by physician  
 
• 
Blood tests: 
o Comprehensive metabolic panel 
o Hepatic panel 
o Lipid panel 
o CBC, Diff, Sed Rate,  
o Retic 
o PT, PTT  
o EBV antibodies 
o CMV IgG 
o RPR 
o CMV antibodies 
o Ab to Hep B core Ag, total Hepatitis B surface antigen Hepatitis B surface antibody 
Hepatitis C antibody 
o HIV I/II screen 
o HTLV1 antibody 
o Blood to QC for monoclonals for chimerism testing  
• 
Urine tests: 
o Urinalysis 
o Urine culture 
o 24-hour urine collection for total protein and creatinine clearance  
 
• 
Chest x-ray (PA and LAT)  
• 
EKG 
 57 


 
 
 
Collecting Donor Adverse Events 
 
Adverse events related to study procedures will be collected from the time the donor is enrolled until 
10 days after all study procedures have been completed. Adverse events will be followed until they have 
resolved or until 30 days after the donor terminates from the study, whichever comes first. 
 
Reporting Donor Adverse Events 
 
All donor adverse events except those ≤ grade 2 will be reported . 
 58 


 
 
Appendix 5: MEDI-507 Dose Preparation Instructions 
 
1.  GENERAL INSTRUCTIONS 
 
 MEDI-507 is provided as a preservative-free, sterile solution at a concentration of 3.75 mg/mL. 
Each single-use vial contains approximately 4 mL of solution (15mg/vial). 
 
 The solution appears clear with occasional protein strands and particles. 
 
 MEDI-507 must be stored between 2° and 8°C (36–46°F). 
 
 The solution must not be frozen. 
 
2.  DOSE PREPARATION/ADMINISTRATION: 
 
 Select the appropriate number of vials of MEDI-507 required to prepare the patient’s dose. 
 
 MEDI-507 vials should come to room temperature prior to dose preparation. 
 
 Inspect each vial selected for dose preparation. 
 
 To avoid foaming, the vial should not be shaken. A vial should only be used once to prepare a 
single dose. 
 
 The solution in each vial should be carefully inspected for turbidity. If the solution is not clear, 
quarantine the vial(s) at refrigerated 2° and 8°C (36–46° F) temperature for institution drug 
accountability. 
 
 MEDI-507 must be prepared using aseptic technique. 
 
 MEDI-507 must be diluted for intravenous administration in a polyvinyl chloride (PVC) infusion 
bag containing 0.9% Sodium Chloride for injection. 
 
 Once a patient’s dose is prepared, it must be administered within 24 hours. 
 
 If it is not administered within this interval, a new dose must be prepared. 
 
 The pharmacist or site personnel should slowly draw the calculated dose volume plus 0.5 mL 
from the vial(s) using an appropriately sized syringe (additional 0.5 mL for priming filter and 
needle). Attach a 25 mm 0.22 micron Millex GV filter to the syringe, attach a new needle and 
slowly prime the syringe to the calculated dose volume. The dose volume of MEDI-507 is then 
added to a polyvinyl chloride (PVC) infusion bag containing 0.9% Sodium Chloride, USP. 
 
3.  ANCILLARY ITEMS REQUIRED: 
 
 25 mm 0.22 micron Millex GV filter. 
 Polyvinyl chloride (PVC) infusion bag containing 0.9% Sodium Chloride, USP 
 59 


 
Appendix 6: Long-term results of HLA mismatched combined kidney and bone marrow 
transplantation without maintenance immunosuppression  
 
Tatsuo Kawai M.D., David H. Sachs M.D., Megan Sykes M.D., Ben Spranger M.D., Ryan J Pena M.D., Thomas R. Spitzer M.D., Nina 
Tolkoff-Rubin M.D., Susan L. Saidman, Ph.D., Frederic I. Preffer, Ph.D., Waichi Wong M.D., Brittany Shonts, Sam LoCascio, Heather 
Morris M.D., Winfred W. Williams, Jr. M.D., Rex-Neal Smith, M.D., Robert B. Colvin, M.D. and A. Benedict Cosimi, M.D.  
for the Immune Tolerance Network 
 
Contribution:  
            Tatsuo Kawai, A. Benedict Cosimi, David H. Sachs, Megan Sykes, Thomas Spitzer and Robert B. Colvin worked for study 
design, clinical management, data analyses and manuscript writing.  Nina Tolkoff-Rubin, Waichi Wong, Winfred W. Williams and 
Rex-Neal Smith participated in clinical management. Susan L. Saidman, Fred Preffer, Ben Sprangers, Brittany Shonts, Sam 
LoCascio, Heather Morris performed in vitro assays and data analyses. 
 
Acknowledgement: 
           This research was performed as a project of the Immune Tolerance Network (N01-AI-15416), an international clinical 
research consortium headquartered at the University of California San Francisco and supported by the National Institute of 
Allergy and Infectious Diseases and the Juvenile Diabetes Research Foundation. Mechanistic studies were supported by NIH grant 
RO1 AI084074. No potential conflict of interest relevant to this article was reported. We thank the Clinical Trials Group of the 
Immune Tolerance Network (ITN) and Eleanor Ramos, M.D., for their participation in the planning and conduct of these studies; 
the ITN Drug Withdrawal Committee for their help in determining appropriate conditions and means for withdrawal of 
immunosuppressive therapy; 
           
 
Summary: 
Background: We report  the long-term results (up to 10 years) of HLA mismatched kidney transplantation without maintenance 
immunosuppression (IS) following combined kidney and bone marrow transplantation (CKBMT).  
METHODS: Five previously reported subjects underwent CKBMT after a nonmyeloablative conditioning regimen (NKD03) 
including cyclophosphamide, thymic irradiation, anti-CD2 mAb with or without pre-transplant rituximab. Five subsequent subjects 
received a revised regimen (ITN036), in which four doses of peri-transplant rituximab were added.  
RESULTS: All 10 subjects developed transient chimerism becoming undetectable by day 21 without GVHD. Associated with the 
loss of chimerism, 9/10 developed transient acute kidney injury (AKI) beginning around day 10. Two kidneys failed: one at week 2 
secondary to humoral rejection and one at 6 months secondary to thrombotic microangiopathy. IS was discontinued 8-14 months 
post-transplant in the remaining 8 subjects.  One developed acute rejection 2 months later and has remained on chronic IS. Five 
of the remaining 7  are off IS with no evidence of rejection for periods of 3-10 years. In two subjects, treatment with 
mycophenolate mofetil alone was initiated 7-8 years after IS withdrawal due to recurrent MPGN in one and probable chronic 
humoral rejection in the other.  Despite in vitro T cell assays showing loss of anti-donor T cell responses by 6 –15 months after 
transplantation, donor specific antibody (DSA) became detectable in 4/5 NKD03 subjects. In contrast, DSA has not been 
detectable in the ITN-036 subjects who received more intensified anti-B cell treatment.  
CONCLUSIONS: Long-term stable tolerance appears inducible despite induction of only transient chimerism via CKBMT.  Our 
observations emphasize the necessity for adequate B cell depletion during the initial 6 months until T cell tolerance is established. 
Observations in both the successful and unsuccessful cases suggest additional modifications of this approach that will lead to the 
development of this approach. 
 
 Introduction: 
          Short-term results following organ transplantation have been significantly improved by the use of increasingly efficacious 
immunosuppressive agents. However, their chronic use results in significant morbidity, especially from an increased incidence of 
cardiovascular disease,1  infection,2  malignancies,3  de novo diabetes4 and other metabolic derangements.  Unfortunately, the 
potent immunomodulatory effects of current therapeutic protocols do not  prevent the development of chronic rejection, despite 
their administration being pushed to toxic levels. Therefore, induction of tolerance, defined as the absence of destructive 
immune responses to a transplanted tissue without ongoing immunosuppressive therapy, remains the ultimate goal of organ 
transplantation.  
 60 


 
          Since the seminal work reported by Billingham, Brent and Medawar on neonatal tolerance in 1956, numerous tolerance 
induction strategies have been identified in rodents. However, only a very limited number of these have been successfully 
translated to large animals and even fewer to primates. Among the few protocols that have been applied in humans, induction of 
donor chimerism, either transient or permanent, currently appears to be the most promising strategy to achieve renal allograft 
tolerance. Initial results of clinical trials for tolerance induction in three centers have so far been reported.  Using TLI and DBMT, 
the Stanford group reported successful induction of stable chimerism and renal allograft tolerance in HLA identical kidney 
transplant recipients.5,6  More recently, Leventhal et al. at Northwestern have reported use of an intensive conditioning regimen 
and donor hematopoietic stem cells for induction of tolerance in HLA-mismatched kidney transplant recipients.7  Although the 
follow-up is still brief, persistent donor chimerism without GVHD has been reported, allowing weaning from all maintenance 
immunosuppression by 1 year in half of the patients.   
         At Massachusetts General Hospital, based on decades-long basic studies in animal models,8-11  we have applied combined 
kidney and donor bone marrow transplantation (CKBMT) for induction of allograft tolerance in both HLA matched12-14 and 
mismatched kidney transplant recipients.15  The early results of the initial five mismatched patients who underwent CKBMT have 
been reported.15 We subsequently extended this approach with a revised regimen to five additional patients. We report here our 
observations in this later cohort as well as the longer-term follow-up (up to 10 years) of the previous recipients of HLA 
mismatched CKBMT. 
 
METHODS 
Study Subjects:  10 subjects with end stage renal disease, aged 22-46, have been enrolled into the studies. All had one HLA 
haplotype-mismatched parent or sibling donors (Table 1). 
 Conditioning Regimen:  The original preparative conditioning regimen (Fig. 1, NKD03) consisted of 60 mg/kg/d of 
cyclophosphamide administered i.v. on days –5 and –4 with respect to transplantation; 0·6 mg/kg/dose of humanized anti-CD2 
mAb (MEDI 507, MedImmune Inc., Gaithersburg, MD) on days -2, -1, 0 and +1; 5 mg/kg cyclosporine A (CyA, Novartis 
Pharmaceuticals Inc., East Hanover, NJ) i.v. on day –1; and thymic irradiation (700 cGy) on day –1. Hemodialysis was performed 
before and 14 hours after each dose of cyclophosphamide. On Day 0, kidney transplantation was followed by i.v. infusion of 
unprocessed donor bone marrow (DBM). Oral CyA (Neoral, Novartis Pharmaceuticals, Inc.) was administered postoperatively at 8 
to 12 mg/kg/day with target trough blood levels of 250-350 ng/ml, then tapered and discontinued over several months.   
The protocol was modified after treatment of the third subject (see Results), to include 1) administration of Rituximab, 375 
mg/m²/dose on days -7 and -2; and 2) administration of prednisone, 2 mg/kg/d starting on the day of transplantation and then 
tapering over the next 10 post-transplant days (modified NKD03). Since subjects treated with this modified NKD03 still developed 
donor specific antibodies (DSA) after discontinuation of immunosuppression, the regimen was further modified (Fig.1) to add two 
more doses of Rituximab (375 mg/m²/dose) on days 5 and 12, more prolonged administration of prednisone until day 20, and 
tacrolimus in place of CyA for the 5 most recently treated subjects (ITN036). Tacrolimus was slowly tapered over several months 
and completely discontinued at 8 months after confirming no rejection by a 6 month protocol biopsy.  All treatment regimens 
were approved by the Massachusetts General Hospital Institutional Review Board (IRB) and developed in collaboration with the 
Immune Tolerance Network (ITN). 
Biopsies: Kidney allograft biopsies were taken per protocol at day 0, 6, 12, 24 and 36 months.  Later protocol biopsies were done 
from 5-8 years (Fig. 2).  Indication biopsies were taken for episodes of graft dysfunction.  All biopsies were processed for routine 
light microscopy, immunofluorescence (including C4d stains) and electron microscopy by techniques previously reported 15,16. 
In Vitro Immunologic Assays: Standard MLR and CML assays were performed using the methods detailed previously.13  LDA to 
quantify cytotoxic T-lymphocyte precursor frequencies and IL-2-producing Th frequencies were performed as described.17 
Detection of donor specific antibodies: Serially collected pre and post transplant sera samples were tested for the presence of 
HLA antibodies using ELISA kit (LAT Class I & II, One Lambda, Canoga Park, CA).  
RESULTS:   
 61 


 
Study subjects:  
           A total of 10 subjects, age 22-46, 6 males and 4 females, were enrolled into these studies.  Their original kidney diseases 
include Alport’s syndrome (n=4), polycystic kidney disease (n=2), membrano-proliferative glomerulonephritis (MPGN) type 
1(n=2), reflux uropathy (n=1) and focal glomerulosclerosis (n=1) (Table 1). The first three subjects (#1 - #3) received the NKD03 
regimen; the next two subjects (#4 and #5) received the modified NKD03 regimen. The last five subjects(#6 - #10) received the 
ITN036 protocol (Fig. 1).  
Induction of transient chimerism:  
            As in the previously reported patients, all additional subjects developed transient multilineage mixed chimerism which 
became undetectable by 2-3 weeks post-CKBMT.15,18  
Engraftment syndrome and acute kidney injury (AKI):  
           We previously described the cytokine syndrome-like manifestations observed after CKBMT as “engraftment syndrome”.15,16  
In fact, the symptoms have been temporally associated with the loss of peripheral chimerism as well as of the return of host-
derived hematopoietic elements. The most troublesome manifestation of this syndrome is acute kidney injury (AKI), which was 
observed after day 10 in all patients except for Subject #1. The biopsies taken during AKI showed severe endothelial injury with 
CD8+ T cell infiltration, as reported previously in detail.16  The peak serum creatinine (Cr.) level ranged from 3·5 to 15·4 mg/dl 
during days 10-20. Among the nine subjects who developed AKI, three recovered without additional treatment, two with 
Thymoglobulin and plasma exchange, one with Thymoglobulin alone and one with pulse steroid therapy. Two kidney allografts 
failed to recover due to associated humoral rejection (Subject #3) and thrombotic micro-angiopathy (Subject #8). 
Long-term clinical course of subjects in NKD03 (Subjects #1-5)  
          Initial results, after follow-up periods of up to 4 years, in the first five patients, were previously reported.15  
As in that report, except for Subject #3, who retrospectively probably had DSA prior to transplant and suffered early graft failure 
due to acute antibody-mediated rejection, all renal allografts are functional with the longest survival now exceeding 10 years 
(Subject #1). Four protocol biopsies performed in Subject #1 up to 7·5 years after CKBMT showed no evidence of rejection (Figs. 
3A-C). Subject #2 remained stable until year 7 following immunosuppression withdrawal (Fig. 2). At that point, urinary protein 
first became detectable. Allograft biopsy revealed no rejection but recurrence of his original disease, MPGN type I (C3 
glomerulopathy) (Figs. 3D-F). Mycophenolate mofetil (MMF) monotherapy for recurrent MPGN was initiated after the 8th year. He 
is currently stable without worsening proteinuria.  Subject #4 received the modified NKD03 regimen (Fig. 1). As previously 
reported, protocol biopsies up to day 731 stained positive for C4d,15  but did not have features of active rejection.  However, his 
five-year protocol biopsy revealed glomerular basement membrane duplication by light and electron microscopy with capillaritis 
and continued C4d deposition with minimal interstitial fibrosis (Fig. 3I). Although his kidney allograft function has remained stable 
with serum Cr of 1·6-1·9 mg/dl (Fig. 2), proteinuria became detectable after 7 years post-transplant, and a brief course of IVIG 
and ongoing MMF therapy has been recently initiated. Subject #5 remained stable for 5 years with no evidence of rejection or 
C4d deposition. Subsequently, after suffering multiple severe episodes of gout, his renal function deteriorated and C4d 
deposition became detectable for the first time in the biopsy at 6 years. He was treated with high dose IVIG (2g/kg) and 2 doses 
of rituximab. After these treatments, his renal function stabilized. A protocol biopsy at 6.3 months showed minimal transplant 
glomerulopathy (cg1)  (Figs. 3J, K) with negative C4d staining again became negative (Fig. 3L). He is currently doing well without 
maintenance immunosuppression. 
Clinical course of subjects in ITN036 (Subjects #6-10) 
           Subject # 6 developed AKI after day 10 but recovered without additional treatment. His immunosuppression was slowly 
tapered and completely discontinued at 8 months after CKBMT. He is currently doing well more than 3·5 years after 
transplantation, without ongoing immunosuppression, and with a serum Cr. level of 1·5 mg/dl. A recent biopsy showed no 
evidence of active rejection (Figs.3M and N). There was de novo C4d staining involving peritubular capillaries (Fig.3O), although 
he continued to have no evidence of DSA by ELISA assay. Immunosuppressive therapy for Subject #7 was discontinued at 8 
months. She is currently over 3 years after CKBMT with normal kidney function (serum Cr. 0.8 mg/dl) (Fig. 2) with no evidence of 
rejection or C4d staining in the 2 year protocol biopsy (Figs. 3P-R). Subject # 8 failed to recover from AKI, and the biopsy 
performed on day 22 revealed arterial intimal matrix expansion with infiltrating mononuclear cells and arterial fibrinoid necrosis 
without C4d deposition in peritubular capillaries. No DSA was detectable.  Differential diagnosis included acute cellular rejection 
type III versus intra-renal thrombotic microangiopathy, possibly due to tacrolimus toxicity. Tacrolimus was discontinued and three 
 62 


 
doses of anti-thymocyte globulin were administered with MMF. Despite these treatments, her kidney function gradually failed 
and she was returned to CAPD at 7 months after transplantation. Subject #9 developed transient AKI after day 10 and recovered 
without additional treatment. Her immunosuppression was slowly tapered and was discontinued at 8 months after 
transplantation. She is currently well at 3 years after CKBMT with normal kidney function (serum Cr. 1·0 mg/dl). The protocol 
biopsy at 2 years showed no evidence of rejection (Figs.3S-U). In Subject #10, kidney function gradually returned to normal by 2 
months after AKI and a 6-month protocol biopsy did not show rejection. His immunosuppression was discontinued at 8 months. 
One month later, he developed acute pyelonephritis in the kidney allograft with moderately elevated serum Cr. (2·2 from 1·6 
mg/dl). This was treated with antibiotics and the kidney function recovered to base line. However, 3 weeks after the resolution of 
his infection, he developed severe acute cellular rejection (Banff 2B)(Fig. 3V) with no C4d deposition (Fig. 3X).  DSA were negative. 
He was treated with steroid pulses and anti-thymocyte globulin, following which his renal function improved but never fully 
recovered.  A renal biopsy 6 months later showed interstitial and intimal fibrosis without active inflammation (Fig. 3W).  Although 
he remains well  almost 3 years post-transplant, his compromised kidney function suggests that gradual progression to ESRD is 
likely (Fig. 2).  
In vitro immunological assays 
Anti-donor T cell responses:  
          MLR, CML, CTLp and HTLp assays in NKD03 subjects were previously reported.15,19  All NKD03 subjects developed donor 
specific nonresponsiveness (DSN)  between 3 to18 months. Serial in vitro immunological assays to test anti-donor T cell responses 
were also performed in the four ITN036 subjects who discontinued their immunosuppression.  In these subjects, DSN or donor-
specific hyporesponsiveness (DSH) were observed in MLR by 3 to 18 months (Table 2).  DSN or DSH were also observed by 3 to 18 
months but some responses against the donor returned positive in Subjects #7 and #9. LDA-HTLp also showed DSH by 3 to18 
months, but anti-donor HTLp response was detectable at 18 months in Subject 9.  
Anti-donor B cell responses (Fig. 4B):  
          DSA has never been detected in Subject #1. DSA was transiently detected only once in Subject #2 with no evidence of 
rejection.  Anti-HLA class II DSA has been persistently positive in Subjects #4 and #5. DSA in Subject #4 has been associated with 
C4d deposition and glomerulopathy, whereas DSA in subject #5 has been weak with only transient C4d deposition and no 
rejection (Fig. 3).   
In contrast to NKD03 subjects, no DSA has been detectable in any of the ITN036 subjects by solid phase assays (ELISA). 
B cell depletion(Fig. 4C) : Recovery of CD3-CD19+ cells in two subjects (Subjects #1 and #2) treated with the original NKD03 
regimen was observed by days 50 and 100, respectively.  With two doses of pre-transplant rituximab (modified NKD03), depletion 
of CD3-CD19+ cells was extended to day 150 (Subjects #4 and #5) but complete loss of CD3-CD19+ cells from the peripheral blood 
was not observed. In contrast, peripheral blood CD3-CD19+ cells were <5/mm3 for 6 months in all five ITN036  subjects treated 
with 4 doses of peritransplant rituximab.18  
 
DISCUSSION 
           We report here that induction of long-term (up to 10 years) stable renal allograft function without maintenance 
immunosuppression can be reproducibly achieved after induction of transient lymphohematopoietic chimerism in recipients of 
HLA-mismatched CKBMT.  Since chimerism is transient, there has been no GVHD observed in our preclinical 9,10 and clinical 
studies 15, which is a major advantage of this approach for tolerance induction. We hypothesize that the mechanism of tolerance 
induction after transient chimerism in these recipients differs from that observed in murine models, in which chimerism persists 
indefinitely.8,20  Our NHP studies have consistently demonstrated the necessity for DBM engraftment resulting in measurable 
donor chimerism, especially in lymphoid lineages, for induction of tolerance.9,10,21  We have therefore concluded that the 
mechanism of tolerance induction by mixed chimerism in primates is likely to involve both central and peripheral pathways.  We 
postulate that initially, donor cells traveling to the thymus lead both to deletion of newly developing T cells and generation of 
regulatory cells which are required to down-regulate any anti-donor responses that were not eliminated at the time when 
chimerism was established.  Consistently, we have demonstrated marked enrichment for Tregs in the first 6-12 months following 
conditioning in the patients in both of these series (please cite Andreola AJT here) and additional studies are suggestive of an 
early wave of Treg emigration from the thymus in these patients (B. Sprangers et al, manuscript in preparation). However, we 
have only occasionally, and only in the first year post-transplant, been able to demonstrate augmentation of anti-donor reactivity 
by depleting Tregs for in vitro assays,19  We therefore postulate that donor-specific Tregs emigrating from the thymus may 
concentrate in the renal allograft itself, and we are currently addressing this possibility in ongoing studies.  However, given the 
complete and long-lasting donor-specific unresponsiveness in Treg-depleted T cells of our patients and the apparent absence of 
donor-specific T cell precursors or of suppressive activity suggested by late LDAs , 19 we have suggested that donor-specific T cells 
are ultimately deleted by continual encounter with donor antigens in a non-inflammatory context in the graft.19 
 63 


 
In our monkeys, costimulatory blockade, with agents directed against CD40/CD15410 or B7/CD28 (manuscript in 
preparation) were helpful in achieving consistent  tolerance.  In our clinical protocol, we have used anti-CD2 monoclonal antibody 
which provides both T-cell depletion and costimulatory blockade via the CD2/LFA-3 interaction 15.  Our studies have also 
emphasized that the kidney allograft itself appears to play a critical role in the induction and maintenance of tolerance. This point 
is illustrated directly by our in vitro studies, in which patients receiving combined kidney and BMT develop donor-specific 
unresponsiveness,15,19  whereas those receiving similar BMT regimens in a cancer treatment protocol, without a kidney graft, 
demonstrated preserved anti-donor responses following loss of peripheral blood chimerism.17  Consistently the same 
conditioning/transient chimerism regimen that  achieves renal allograft tolerance has failed to induce tolerance of isolated heart 
allografts in monkeys.22 Interestingly, heart allograft tolerance can be achieved by co-transplanting the kidney from the same 
donor. and heart allografts that had survived long-term are promptly rejected if the kidney allograft is removed.23 Presumably, 
the donor-specific regulatory cells generated during the chimeric state require continuing interaction with as yet undefined 
specific cells or antigens in the kidney allograft for maintenance of the tolerance. One potentially important renal cell is the renal 
tubular epithelial cell, that has been reported to participate in the induction of allospecific tolerance in rodents and humans.24-26     
          Despite the encouraging results of successful long-term tolerance induction in our initial clinical trials, several obstacles to 
more widespread application of this approach have been identified. The most troubling of these is the “engraftment syndrome”.  
AKI is a major manifestation of engraftment syndrome and has been observed at approximately day 10 in all subjects except for 
Subject #1.  This syndrome has been described previously following both autologous and allogeneic bone marrow 
transplantation, which has been associated with the recovery of either host or donor type  hematopoietic elements 27.  We note 
that the AKI of engraftment syndrome has never been observed in our MHC-mismatched monkey model, in which chimerism is 
also lost, but at a more gradual pace, usually over 2-3 months.9,10,28  Our current interpretation of these findings is that the pre-
transplant cyclophosphamide-based regimen chosen for the clinical trials,15  in contrast to the non-myeloablative total body 
irradiation used in the monkey preparative regimen,9,10,28,29  may allow rapid homeostatic recovery of host memory T cells, which 
may be associated with significant effector function, as suggested by the observation of CD8 T cell activation immediately 
following conditioning 16 and rapid rejection of the donor hematopoietic graft.  Further supporting this hypothesis is the 
observation that AKI has also never been observed in our HLA-matched CKBMT recipients, in whom chimerism as in the NHP 
recipients typically disappears more slowly, over a periods of 2-3 months.12,14  However, marrow rejection may not be the driving 
force for this syndrome, since CD8 activation is observed as early as Day 0,16 before sensitization could occur. Unfortunately, our 
efforts to test this hypothesis, by using a cyclophosphamide-based regimen in monkeys, have been precluded by unusually severe 
toxicities of this agent in this species.30   
        The second obstacle observed in the first study (NKD03) subjects was the frequent development of either transient or 
persistent DSA, despite specific loss of anti-donor T cell responses. In NKD03, DSAs were detectable in most subjects except for 
Subject #1. Despite occasional (Subject #2) or persistent (Subjects #4 and #5) detection of DSA, only Subject #4 developed chronic 
glomerulopathy with C4d deposition. Studies are underway to evaluate the possible usefulness of the Luminex approach to 
identifying DSA complement fixation (C1q) as a means of clarifying the clinical relevance of these variably detected antibody 
levels in allograft recipients not on chronic immunosuppression. In contrast to NKD03 subjects, with the more intensified anti-B 
cell treatment afforded by adding rituximab to the conditioning regimen for ITN036 subjects, there has been no evidence of DSA.  
Since anti-HLA antibodies are thought to represent T cell-dependent responses, these observations suggest that B cells in NKD03 
subjects might have been sensitized before T cell tolerance was established by mixed chimerism.15  Since anti- donor HTLp 
responses can be observed up to 18 months after CKBMT (Fig. 4A), it may be critical to prevent B cell activation during the early 
post-transplant period in order to establish robust tolerance. Although rituximab does not affect serum immunoglobulin levels, 
antigen-specific antibody titers, or antibody secreting plasma cell numbers, it does effectively deplete peripheral mature B cells, 
likely including germinal center B cells 31. The germinal center is the nidus of immunological activation, where close collaboration 
between antigen driven T and B cells occurs 32. Thus B cell depletion by rituximab can prevent humoral immune responses and 
antibody class switching 31 and its use in ITN036 appears to have largely removed this obstacle to tolerance induction via this 
approach.  
          The third obstacle to more widespread application of our tolerance technology is its requirement for living donor 
transplantation, as this strategy involves treatment of the recipient beginning 6 days prior to transplantation. To address this 
obstacle, we have recently developed a novel regimen for “delayed tolerance” induction, in which the recipient initially 
undergoes organ transplantation with conventional immunosuppression, followed by conditioning and DBM transplantation at a 
later date. In our NHP studies,  we have shown that such “delayed tolerance" can be induced by modifying the post-transplant 
treatment to avoid generation of donor-specific memory T cell responses prior to induction of mixed chimerism 29,33.  In addition 
to making it possible to utilize deceased donors for renal transplants, successful application of this new procedure could permit 
 64 


 
treatment of patients with functioning transplants who want to discontinue immunosuppression for a variety of reasons and 
could also help to extend tolerance to other non-renal organs.  
             In conclusion, our clinical studies have shown that immune-suppression free stable renal allograft function can be 
reproducibly achieved for periods now extending to 10 years by induction of transient chimerism through DBMT. Further 
modifications of the protocol are planned to address the “engraftment syndrome” related AKI, which is the current major barrier 
to continued development of this approach.  
 
Figure Legends 
Fig. 1: Anti-donor responses- T cell responses 
Anti-donor or anti-third party LDA-HTLp in ITN-036 subjects are shown. LDA-HTLp also showed DSH by 3 to18 months, but anti-
donor HTLp response was detectable at 18 months in Subject 9.  
1A: Detection of donor specific antibody (DSA) 
DSAs are detected by ELISA.  
NKD03: Subject #1: DSA has never been detectable. Subject #2: DSA was only transiently detected once around 7 years.  
Subject 3: Although pre-transplant DSA was negative by ELISA, retrospective Luminex showed positive anti-class I DSA (B44) 
before transplantation. The subject developed acute humoral rejection on day10 with DSA (B44 and DR4). Subjects 4 and 5: 
DSA became positive soon after stopping his immunosuppression with or without C4d deposition and chronic rejection (See 
Fig.3G-L).  
ITN036: In contrast to NKD03 subjects, No DSA has been detectable in any ITN036 subject.   
 
Figure 2: CD3-CD19+ cell depletion after CKBMT 
In two subjects treated with the NKD03 regimen, the recovery of CD3-CD19+ cells (B cells) were found by day 50 (Subject #1) 
and day 120 (Subject #2)(black lines). With addition of two doses of pre-transplant rituximab (modified NKD03), B cells were 
never depleted completely and recovered by days 150 and 180 (blue lines). With 4 doses of peri-transplant rituximab (ITN036), 
B cells were significantly depleted (less than 1-2/mm2) for 180 days (red lines).  
 
Fig. 3: Late renal allograft biopsies (all protocol biopsies unless noted). 
A-C (Subject #1 at 7.5 years):  The protocol biopsy shows no evidence of rejection by light microscopy (LM) (A).  The glomeruli 
are normal by electron microscopy (EM) (B) and no C4d staining is detectable by immunofluorescence (IF)( C) 
D, E, F (Subject #2 at 8 years): An indication biopsy for proteinuria shows prominent lobular mesangial expansion with 
widespread glomerular basement membrane (GBM) duplication (D, arrow).  Granular dense deposits in the duplicated GBM 
are seen by EM (E). Granular and segmental staining for C3 along the GBM and in the mesangium is evident by IF, but no 
immunoglobulin was detected (F),  indicative of recurrent C3 glomerulopathy (originally classified as MPGN, type I)..  
G,H,I (Subject #4 at 5 years): Widespread GBM duplication (arrow) and glomerulitis is seen by LM (G).  EM shows prominent 
duplication of the GBM without deposits and reactive endothelial cells (H).  C4d deposition is detected in peritubular capillaries 
(I). These findings are indicative of chronic, active antibody mediated rejection, which at this time was subclinical.  
J,K,L (Subject #5 at 6 years): The biopsy shows minimal glomerulitis by LM (j), slight segmental GBM duplication by LM (J) and 
EM (K) and no C4d deposition by IF (L)   
M,N,O (Subject #6 at 2 years): LM shows normal glomeruli with rare foci of interstitial mononuclear inflammation affecting 
<5% of the cortex.  EM shows minimal focal GBM duplication and normal endothelium (N).  C4d was present in the majority of 
the peritubular capillaries (O).   
P,Q, R (Subject #7 at 2 years): LM is within normal limits (P).  EM reveals a normal GBM and endothelium; foot process 
effacement is present in a minority of the capillaries (20%) (Q). There is no C4d deposition (R).   
S,T, U (Subject #9 at 2 years): The kidney biopsy is within normal limits and shows no evidence of rejection by LM (S) with 
normal glomeruli by EM (T).  There is no evidence of recurrent MPGN.  No C4d is detected (U).   
V,W,X: (Subject #10): Indication biopsy at 9.5 months shows acute cellular rejection with endarteritis (V).  A protocol biopsy six 
months later shows complete resolution of the inflammatory process and residual interstitial and intimal fibrosis (W).  No C4d 
deposition is detectable at 9.5 months (X) or at other times.  
           Light microscopy stains: H&E, A, M, V; PAS, D, G, J. P, S. Immunofluorescence stains: C4d, C, F, I, L, O, R, U, X.  
 
 
 
 
 65 


 
References 
 
1. Lentine KL, Brennan DC, Schnitzler MA. Incidence and predictors of myocardial infarction after kidney transplantation. J Am Soc Nephrol 
2005;16(2):496-506. 
2. Alangaden GJ, Thyagarajan R, Gruber SA, et al. Infectious complications after kidney transplantation: current epidemiology and 
associated risk factors. Clin Transplant 2006;20(4):401-9. 
3. Marcen R. Immunosuppressive drugs in kidney transplantation: impact on patient survival, and incidence of cardiovascular disease, 
malignancy and infection. Drugs 2009;69(16):2227-43. 
4. Marchetti P, Navalesi R. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000;23(7):482-90. 
5. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J 
Med 2008;358(4):362-8. 
6. Scandling JD, Busque S, Shizuru JA, Engleman EG, Strober S. Induced immune tolerance for kidney transplantation. N Engl J Med 
2011;365(14):1359-60. 
7. Leventhal J, Abecassis M, Miller J, et al. Chimerism and Tolerance Without GVHD or Engraftment Syndrome in HLA-Mismatched 
Combined Kidney and Hematopoietic Stem Cell Transplantation. Sci Transl Med 2012;4(124):124ra28. 
8. Sharabi Y, Sachs DH. Mixed chimerism and permanent specific transplantation tolerance induced by a nonlethal preparative regimen. J 
Exp Med 1989;169(2):493-502. 
9. Kawai T, Cosimi AB, Colvin RB, et al. Mixed allogeneic chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 
1995;59(2):256-62. 
10. Kawai T, Sogawa H, Boskovic S, et al. CD154 blockade for induction of mixed chimerism and prolonged renal allograft survival in 
nonhuman primates. Am J Transplant 2004;4(9):1391-8. 
11. Sykes M. Mixed chimerism and transplant tolerance. Immunity 2001;14(4):417-24. 
12. Spitzer TR, Delmonico F, Tolkoff-Rubin N, et al. Combined histocompatibility leukocyte antigen-matched donor bone marrow and renal 
transplantation for multiple myeloma with end stage renal disease: the induction of allograft tolerance through mixed 
lymphohematopoietic chimerism. Transplantation 1999;68(4):480-4. 
13. Fudaba Y, Spitzer TR, Shaffer J, et al. Myeloma responses and tolerance following combined kidney and nonmyeloablative marrow 
transplantation: in vivo and in vitro analyses. Am J Transplant 2006;6(9):2121-33. 
14. Spitzer TR, Sykes M, Tolkoff-Rubin N, et al. Long-Term Follow-Up of Recipients of Combined Human Leukocyte Antigen-Matched Bone 
Marrow and Kidney Transplantation for Multiple Myeloma With End-Stage Renal Disease. Transplantation 2011. 
15. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 
2008;358(4):353-61. 
16. Farris AB, Taheri D, Kawai T, et al. Acute renal endothelial injury during marrow recovery in a cohort of combined kidney and bone 
marrow allografts. Am J Transplant 2011;11(7):1464-77. 
17. Shaffer J, Villard J, Means TK, et al. Regulatory T-cell recovery in recipients of haploidentical nonmyeloablative hematopoietic cell 
transplantation with a humanized anti-CD2 mAb, MEDI-507, with or without fludarabine. Exp Hematol 2007;35(7):1140-52. 
18. LoCascio SA, Morokata T, Chittenden M, et al. Mixed chimerism, lymphocyte recovery, and evidence for early donor-specific 
unresponsiveness in patients receiving combined kidney and bone marrow transplantation to induce tolerance. Transplantation 
2010;90(12):1607-15. 
19. Andreola G, Chittenden M, Shaffer J, et al. Mechanisms of donor-specific tolerance in recipients of haploidentical combined bone 
marrow/kidney transplantation. Am J Transplant 2011;11(6):1236-47. 
20. Sykes M, Sachs DH. Mixed chimerism. Philos Trans R Soc Lond B Biol Sci 2001;356(1409):707-26. 
21. Kimikawa M, Sachs DH, Colvin RB, Bartholomew A, Kawai T, Cosimi AB. Modifications of the conditioning regimen for achieving mixed 
chimerism and donor-specific tolerance in cynomolgus monkeys. Transplantation 1997;64(5):709-16. 
22. Kawai T, Cosimi AB, Wee SL, et al. Effect of mixed hematopoietic chimerism on cardiac allograft survival in cynomolgus monkeys. 
Transplantation 2002;73(11):1757-64. 
23. Tonsho M MT, Klarin D, Boskovic S, Nadazdin O, Benichou G, Cosimi AB, Smith NR, Colvin RB, Kawai T, Madsen JC. . Induction of 
Tolerance to Heart Allografts by Donor Kidney Co-Transplantation in Nonhuman Primates (NHPs). . American Transplant Congress 2012  
2012, Boston: 157. 
24. Braun MY, McCormack A, Webb G, Batchelor JR. Evidence for clonal anergy as a mechanism responsible for the maintenance of 
transplantation tolerance. Eur J Immunol 1993;23(7):1462-8. 
25. Frasca L, Marelli-Berg F, Imami N, et al. Interferon-gamma-treated renal tubular epithelial cells induce allospecific tolerance. Kidney Int 
1998;53(3):679-89. 
 66 


 
26. Starke A, Lindenmeyer MT, Segerer S, et al. Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses. Kidney 
Int;78(1):38-47. 
27. Spitzer TR. Engraftment syndrome following hematopoietic stem cell transplantation. Bone Marrow Transplant 2001;27(9):893-8. 
28. Kawai T, Poncelet A, Sachs DH, et al. Long-term outcome and alloantibody production in a non-myeloablative regimen for induction of 
renal allograft tolerance. Transplantation 1999;68(11):1767-75. 
29. Yamada Y, Boskovic S, Aoyama A, et al. Overcoming Memory T-Cell Responses for Induction of Delayed Tolerance in Nonhuman 
Primates. Am J Transplant 2012;12(2):330-340. 
30. Sogawa H, Boskovic S, Nadazdin O, et al. Limited efficacy and unacceptable toxicity of cyclophosphamide for the induction of mixed 
chimerism and renal allograft tolerance in cynomolgus monkeys. Transplantation 2008;86(4):615-9. 
31. DiLillo DJ, Hamaguchi Y, Ueda Y, et al. Maintenance of long-lived plasma cells and serological memory despite mature and memory B 
cell depletion during CD20 immunotherapy in mice. J Immunol 2008;180(1):361-71. 
32. Parsons RF, Vivek K, Redfield RR, 3rd, et al. B-lymphocyte homeostasis and BLyS-directed immunotherapy in transplantation. Transplant 
Rev (Orlando);24(4):207-21. 
33. Koyama I, Nadazdin O, Boskovic S, et al. Depletion of CD8 memory T cells for induction of tolerance of a previously transplanted kidney 
allograft. Am J Transplant 2007;7(5):1055-61. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 


 
Fig. 1
 
 
pre
1 y
2 yrs
3 yrs
4 yrs
5 yrs
6 yrs
7 yrs
8 yrs
9 yrs
10 yrs
#1
-
-
-
-
-
-
-
-
-
#2
-
-
-
-
DQ9
-
NKD03
#3
-
DR4
#4
-
-
DR17
DR17
DR17
DR17
#5
-
-
-
DR53
DR53
DR53 
DR53
#6
-
-
-
-
-
#7
-
-
-
-
-
ITN036
#8
-
-
#9
-
-
-
-
#10
-
-
-
-
Fig. 1A
 
 68 


 
Fig. 2
 
A
B
C
D
E
F
G
H
I
J
K
L
N
O
P
Fig. 3
M
Q
S
T
U
X
V
W
R
K
 
 
 
 
 
 
 
 
 
 69 


 
Appendix 7: Schedule of Events for Safety Follow-up 
1 Can discontinue GVHD assessment once chimerism is not detectable.  
2 Perform test until chimerism is no longer detectable. Chimerism testing will be done by Flow Cytometry. In the event 
that HLA antigens (needed for Flow cytometry analysis) cannot be detected by available monoclonal antibodies, 
STR/Microsatellite methodology will be used. 
 
Time 
 
 
 
 
 
 
 
 
 
M6 
 
Y1 
 
 
 
Y2 
Week 
0 
2 
6 
8 
10 
13 
14 
18 
22 
26 
39 
52 
65 
78 
91 104 
Follow-up for participants prematurely discontinued from study therapy (section 3.4.4.2) 
Visit 
 
101 102 
 
103 
 
104 105 106 107 108 109 110 111 112 113 
Assessments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse events 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Concomitant medications 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Hematology 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum and basic 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Thyroid function 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
GVHD assessment1 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Graft survival 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Chimerism2 
 
X 
X 
 
X 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Follow-up for participants prematurely terminated from study (section 3.5.2) 
Visit 
201 
 
 
202 
 
 
 
 
 
 
 
 
 
 
 
 
Assessments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse events 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Concomitant medications X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Physical examination 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Hematology 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Serum and basic 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Thyroid function 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
GVHD assessment1 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Graft survival 
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Chimerism2  
X 
 
 
X 
 
 
 
 
 
 
 
 
 
 
 
 
Follow-up treatment for participants who fail immunosuppression withdrawal (section 4.4.8.5) 
Visit 
301 
 
 
 
 
302 
 
 
 
303 304 305 306 307 308 309 
Assessments 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Adverse events 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Concomitant medications X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Physical examination 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Hematology 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Serum and basic 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Thyroid function 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
GVHD assessment1 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Graft survival 
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
Chimerism2  
X 
 
 
 
 
X 
 
 
 
X 
X 
X 
X 
X 
X 
X 
 70